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CHAPTER 1 INTRODUCTION 
Nanoscaled materials are structures with a size of less than 200 nm, and 
they show different physical and chemical properties compared with their 
bulk correlatives. Application of Gold nanoparticles (AuNPs) has a long 
history which can be tracked back to centuries B.C. by ancient scientists.(1) 
AuNPs are particularly attractive in modern biomedical area due to their 
versatile surface chemistry, ease of imaging, low toxicity, and engineerability 
to take advantage of blood-brain barrier transport mechanisms.(2, 3) AuNPs 
are being widely investigated for sensing, immunoassays, bioimaging for 
diagnostics, targeted delivery of drugs, genetic materials, antigens, and 
diagnostic agents.(4) For example, in combination with radiation, AuNPs 
have proven successful at dissolving deposits of beta-Amyloid, the protein 
involved in Alzheimer’s disease.(5-8) And as a result of the surface plasmon 
resonance (SPR) effect, AuNPs can have a wide range of excitation upon 
receiving wavelength from visible to infrared, which gives a great potential 
of optical applications.(9) 
This dissertation described a method of utilizing gold nanoparticles 





drug delivery systems. The main system involved is a tripartite 
nanoconjugate consists of drug, targeting protein, and AuNP as vehicle, and 
the nanoconjugate has been used to treat respiratory malfunction after 
spinal cord injury and recovery has been obtained after a single 
intramuscular injection. Besides, this dissertation also described using AuNPs 
to increase solubility of drugs by conjugating the poorly-soluble drug with 
AuNPs. The drug-conjugated AuNPs caused cell death and shrink of tumors 
after administration. This dissertation also discussed the cytotoxicity of 
AuNPs in biomedical applications. Different sized AuNPs has been tested 
using human embryonic stem cells (hESCs), and the size-dependent toxicity 
of AuNPs were observed and discussed. 
In chapter 2, a literature review will be presented to show currently used 
methods of AuNPs fabrication and modification based on different aspects 
of applications. Then a detailed description of application of AuNPs in 
biomedical area will be included, and the safety of AuNPs will also be 
discussed. 
Chapter 3 will focus on an engineered nanoconjugates aiming to bringing 





model. Various characterization methods were used to determine the 
composition, size, shape, and stability of the nanoconjugates. And the 
recovery of breathing was detected based on electromyography (EMG) 
technique. Dosage optimization were also included in this chapter. 
Chapter 4 describes an increase of solubility was introduced by 
conjugating an anti-cancer drug with AuNPs through chemical bonding. The 
nanoconjugate were injected locally and cell death were observed. 
Chapter 5 describes a size-dependent toxicity study involving AuNPs with 
core size of 1.5 nm, 4 nm, and 14 nm. All three types of AuNPs were modified 
with surfactants to achieve better biocompatibility, but a considerable 
toxicity was observed for 1.5 nm sized AuNPs when treating with hESCs. In 
the meanwhile, AuNPs with size of 4 nm and 14 nm show no toxicity in this 
study. 
Chapter 6 concludes this work in gold nanoparticle engineering aiming to 
obtain a biocompatible drug delivery system without introducing toxicity.  
CHAPTER 2 LITERATURE REVIEW 
2.1 Fabrication and functionalization of gold nanoparticles (AuNPs) 





With the reduction of gold chloride by phosphorus, Michael Faraday is 
believed to be one of the first who reported the synthesis of stable gold 
nanoparticle back in year 1857.(10) Today well established preparation 
protocols have been developed for AuNPs with various size, shape, and 
surface modification.(11) With ease of adjusting ratio between gold salt (for 
example, HAuCl4), reducing agent, and capping/protecting agent, wet 
chemical synthesis is mostly used to prepare AuNPs with diameters ranged 
from ~2nm to 50nm.(12-15) Also, a cetyltrimethylammonium bromide 
(CTAB)-assisted two-step method was raised by Murphy(16) and El-Sayed(17) 
for gold nanorods synthesis, a seed solution with gold clusters in size of less 
than 2nm is used in the first step followed by addition of surfactant CTAB. 
Besides simple oxidation-reduction based chemical methods, 
photoreduction, electrochemical synthesis, and plasmon-driven synthesis 
are also developed.(11) In the mind of “green chemistry”, Mukherjee, P., et 
al.(18)reported that AuCl4- ions are reduced by the fungus Verticillium sp. to 
obtain monodispersed AuNPs which was the first report the use of 
eukaryotic organisms in AuNP biosynthesis. 





 In the purpose of introducing both biocompatibility and intracellular 
stability, proper surface functionalization is obviously necessary. Capping 
ligands including but not limited to thiolates(19), dithiolates(20), amines(21), 
and carboxylates(21) are all reported in preparation of AuNPs based on 
different reaction mechanisms(22). Coupled with the binding, the shift of 
surface plasmon resonance (SPR), change of redox activity, and change of 
conductivity are observed, which can be used for clinical diagnosis and 
biosensing.(23-25)  By acting as “spacer” and “linker”, thiolated non-toxic 
long chain polymers such as thiolated polyethylene glycol (PEG-SH) has been 
used widely with the favor of strong Au-S bonds(26) and flexibility of 
subsequent functionalization on the other end. However in order to fully 
take advantage of the Au-S bonding: alkanethiolate-stabilized gold 
nanoparticles are very stable in aqueous solution as well as organic solvent, 
a lot efforts have been put in altering the structures of thiolates used to 
stabilized the nanoparticle surface.(27-31) Besides, serum proteins, for 
example, bovine serum albumin (BSA), are also proven effective in providing 





protein corona.(32, 33) All the functionalization also contribute to decreasing 
or/and avoiding toxicity of AuNPs when introduced into physiological models. 
The surface modification can not only modify properties of AuNPs, fate 
of small molecules within physiological environment would also be altered 
after bonded with AuNPs. Such as CTAB, one of the normally used surfactant 
in AuNP synthesis, which is cytotoxic while as free molecules, will become 
nontoxic after binding to gold nanorods.(34) A more practical use of the 
surface modification is engineering of therapeutic molecule delivery devices. 
One recent example is that conjugating a small molecule inhibitor SMI#9, 
which is specific designed for killing cancerous cells, with mercaptosuccinic 
acid coated AuNPs results in a high therapeutic efficiency combined with 
good selectivity.(35) 
Nanoparticle properties and functionalization completeness can be 
qualitatively tested by spectroscopy (e.g. IR, Raman, UV-Vis), electron 
spectroscopy (e.g. TEM, SEM), dynamic light scattering (DLS), 
thermogravimetric analysis (TGA). However, the disadvantages of these 
methods are not ignorable. TEM and SEM are having resolution problems 





small sized AuNPs or gold nanocluster.(36) Because of the correlation model 
it based on, DLS can only be used to measure relative pure spherical particles 
with narrow size distribution.(37) TGA needs sample amount to be at least 
1mg, which is considered a large amount in nano-scale study. 
In order to quantify the composition of AuNPs, Rotello, et al. 
suggested that with a combination of laser desorption/ionization (LDI) and 
inductively coupled plasma (ICP) mass spectrometry both amount of 
functional ligands and conjugate stability can be measured. (38) A 
fluorescence-based method was developed which can be used to 
quantitatively assess surface coverage and hybridization efficiency of gold 
films.(39) 
2.2 Applications of AuNPs in biomedical area 
The application of AuNPs has been broaden widely with the 
development of various detection techniques. This involves detection and 
photothermolysis of cancer cells, biosensing of both microorganisms and 
cells, optical imaging, X-ray enhancement, and targeted delivery of various 
biomolecules. Among these applications AuNPs were used solely or after a 





2.2.1 Photothermal and photodynamic therapy 
Nanostructures have a higher accumulation among cancerous tissues 
because of a disordered vessel structure and a porous membrane. This 
enhanced permeability and retention(EPR) effect has been utilized for 
passive delivery of nanoparticles for a long time.(40) AuNPs, upon absorption 
of light with certain wavelength in visible and near-IR region, will heat up 
rapidly, and as a result, this high temperature will kill the cells around or 
containing AuNPs. This is the basic concept of photothermal therapy using 
AuNPs.(41) 
Using AuNPs in photothermal therapies is rising great interest 
especially after combining with laser radiation which offers a better 
penetration with a limited, controllable damage to cancer cells.(42) This is 
proved to be promising for effective therapy towards chemotherapy-
resistant cancerous types. 
Despite the heat created by the absorption of certain wavelength, 
AuNPs will also undergo a different photochemical mechanism to generate 





cells. This photodynamic method using AuNPs has been applied to 
oncological diseases and skin diseases for decades.(43, 44) 
The main problems for photonic therapies involving AuNPs are that 1) 
the colloidal stability of the particles that are used in the methods, and 2) the 
enhancement of delivery or accumulation of AuNPs in the targeted sites.(45) 
But it is promising due to the favor of great tunability of AuNPs and the ease 
of fabrication without using of certain compounds other than the particle 
itself.  
2.2.2 Bioimaging and visualization 
Thanks to its high electron density as a heavy metal, gold nanoparticles 
have a good resolution under transmission electron microscope (TEM) and 
has been studied since 1970s.(46) High resolution TEM has been used to 
determine the cellular uptake of AuNP and interactions between  AuNP and 
various biomolecules, microorganisms, and microstructures. However, 
particularly in biomedical area, optical microscopy methods using AuNPs are 
becoming more popular recent years. 
After combining with label molecules such as fluorescent dye or 





a real-time style with confocal.(47-49) Especially, with its plasmonic property, 
AuNP can enhance the contrast of target molecules or structures inside cells 
result from the multi-photon resonance.(50-52)  
AuNPs are also proved to have a higher magnitude comparing with 
fluorescence under dark-field microscopy because of smaller scattering cross 
section.(53) After conjugation with antibodies, AuNPs can only bind to 
cancer cells through an antibody-antigen interaction solely between the  
nanoconjugates and the cancerous cells, with dark-field microscopy this 
specific binding can be seen and used to pinpoint cancer cell from normal 
cell at a single-cell resolution.(54)  
2.2.3 Delivery of targeted biomolecules 
As described above, biomolecules can bind to AuNPs through both 
chemical conjugation and the binding type can be tuned to be biodegradable 
or biostable.(55) In most of the study, the biomolecules are anti-cancer 
molecules, and are proved to be effective thanks to EPR effect. 
Other than anti-cancer therapy, AuNP is also a potential candidate for 
gene therapy after conjugation delivery of genetic materials.(56-59)  





2.3.1 Colloidal stability 
AuNPs easily aggregate when encountering with high-ionic-strength 
environment, and in order to make it biocompatible, colloidal stability of 
AuNPs should be carefully engineered, considering the physiological 
condition involves high concentration of salts and a wide range of 
biomolecules such as proteins and enzymes.  
A standard method to guarantee dispersibility, uniformity, and 
biocompatibility is to use surfactants to modify the surface of AuNPs. 
Currently thiol compounds such as glutathione, mercaptopropionic acids, 
cysteine, dihydrolipoic acid, thiolated polyethylene glycol, and their 
derivatives are considered as the most biocompatible surfactants to be 
applied to AuNPs.(60-63) The reason is that Au-S bond is more stable than 
most of the other type of bond between the surface of AuNP and surfactant, 
and the variability of the thiol compounds is offering possibility of further 
modification depending on the demand of the conjugate. Even with a good 
coverage of surfactant, after introduction of physiological condition, the 





standardized investment of the colloidal stability of AuNPs in commonly 
studied aqueous environment. 
2.3.2 Nanotoxicity of AuNPs 
As a well-established yet highly active area, AuNPs are being widely 
used as imaging enhancer, therapeutic agents alone by themselves, and 
engineered targeted delivery carriers for drugs, oligonucleotides, antigens, 
and diagnostic agents.(4, 64-67) AuNP has also been used in consumer 
market for decades considered non-toxic and inert same as its bulk 
compartment. Both scientific research and marketing field have an urgent 
need for systematic nanotoxicity assessment concerning influence of AuNPs 
on human health. 
 Cytotoxicity assessment has been one of the most active area 
considering the amount of various of products applied into market especially 
those related with human health. In vitro assays haven been proven to be 
commonly used due to ease of reproducing, refining, and replacing.(68, 69) 
Here we briefly summarized several assays that are used in standard in vitro 
toxicity evaluation experiments based on different mechanisms. 





A very obvious and straightforward result after inducing analyte for 
toxicity assessment is change of cell growth speed, and/or cell death. By 
comparing cell counts between different treatments the influence of analyte 
can be evaluated. Both live cells counting methods such as hemocytometry 
and colorimetric assays are used. Well established assays such as the 3-(4,5-
dimethylthiazolyl-2)-2,5-dephenyltetrazolium bromide (MTT) based on the 
reduction of tetrazolium dye by cellular mitochondrial dehydrogenase 
present only in viable cells, the purple formazan product is soluble under 
intracellular environment and is easy to be quantified by photometry. Similar 
assays utilizing tetrazolium dyes such as XTT, MTS and the WST-1 are all 
ready-to-use assays for cell viability and toxicity study via monitoring 
enzymatic activity of mitochondrial.(70) Another method, sulforhodamine B 
(SRB) assay, based on measuring cellular protein content can also provide 
comparable sensitivity coupled good reproducibility.(71) 
2.3.2.2 Membrane integrity lost 
Toxicity inducing may also include membrane interfering which may 
result in permeability change and compound leakage. Among dye exclusion 





nonviable cells lacking membrane functions.(72) The blue color staining by 
trypan blue can differentiate the viable cells from the dead and a subsequent 
cell counting can evaluate the viability quantitatively.(72, 73) Another 
reliable and simple assay is lactate dehydrogenase (LDH) leakage method. 
The intracellular loss of LDH and resulting leakage is an indicator of 
membrane dysfunction and measuring the activity of extracellular LDH can 
be used to assess the status of cells.(74) 
2.3.2.3 Metabolic activity decreasing 
Cell metabolism can be also indicated by the concentration of either 
Adenosine triphosphate (ATP) or certain protein. ATP is playing a role in all 
metabolically activity inside cells. The bioluminescent assay can quantify ATP 
concentration using luciferase.(75) Enzymes are important in regulation 
gene expression, metabolic activity, and gene variation, such as Cytochrome 
P450.(76) Both common enzyme-linked immunosorbent assay (ELISA) and 
gel electrophoresis are used testing CYP450s.(76)  
3.3.2.4 Epigenetic affects 
How cells express genes are obviously important in cell viability, and 





epigenetic change is natural, it is also affected with inducing of certain toxic 
materials such as gold nanoparticles.(36) Global DNA methylation status can 
be determined by immunoprecipitation based colorimetric assays.(36)  
Most of in vitro assays are using immortalized cell lines or mature cell 
lines, this makes it difficult to correlate the results from cancerous cells or 
animal cells to healthy, human cells. The specificity of targets needed for 
each assay also increases its uncertainty when disruption of membrane 
and/or mitochondria may be caused by the particle induced. On the other 
hand, to avoid ethic issue and high expense, experimental cell lines and 
animal models are preferred. For example, zebrafish has less than 1% 
heterologous genes corresponded with early embryo development 
compared with that of human, which makes it an ideal model in AuNP 
cytotoxicity study.(78)  
2.3.2.5 Toxicity dependence 
While strategies for cytotoxicity and cell uptake study of AuNPs are 
raised so differently between research labs, the dependence of toxicity is 
well agreed. Surface charge dependent toxicity is quite straightforward that 





negatively charged cell membrane.(79) Meanwhile several different 
mechanisms are postulated describing the size dependent cytotoxicity 
caused by AuNPs based on various experiment models and designs both in 
vitro and in vivo. (80-83)  
First and one of the most common mechanism is intracellular reactive 
oxidative species (ROS) induced by nanoparticles. Pan, et al. (81)showed that 
triphenylphosphine monosulfonate (TPPMS)-capped AuNPs with a gold core 
of diameter 1.4nm is superb toxic result in necrosis caused by oxidative stress 
while 15nm-AuNPs of similar chemical composition are nontoxic. 
Furthermore, reduced toxicity after pretreating cells with anti-oxidants (e.g. 
glutathione) supported the ROS theory. Note that in the same study 
important role of capping ligands has been high-lightened that glutathione 
capped AuNPs with similar diameter (1.1nm) do not induce cell death. 
However, a newly reported thiolate-coated gold nanocluster Au55 is highly 
toxic when treating human embryonic stem cells (hESCs).(36) Second 
mechanism states that cytotoxicity is due to the ultra-small size of Au55 
clusters enables irreversible coordination between the clusters and the 





clusters surprisingly bind to DNA molecules in a large fraction, which is 
believed to affect transcription and/or duplication in the cell. This is due to 
a) the dimensional fitting between gold clusters of ~1.4nm and major 
grooves of DNA; b) the polydentate ligand system of nucleus provides higher 
stability compared to the monodentate capping ligands.(80) Third 
mechanism involves cell membrane interference. One study shows that Au55 
clusters are extremely toxic to hESCs even after pretreatment with thiolate 
capping ligands, and without evidence of entering the cells they concluded 
that some disruptions towards cell membrane occurred.(36) Rotello group 
believes that the toxicity is related with the strong electrostatic interaction 
between the negatively charged bilayer with cationic ligand coated AuNPs, 
which can be addressed by anionic capping.(79) Another group is attributing 
the interference to blockage of membrane ion channels(84), note that in this 
case after thiol-stabilization the toxicity is reduced. 
AuNP cytotoxicity, especially caused by Au55 clusters, appears to be 
capable of being reduced by modifying the AuNPs with proper capping 
ligands such as thiolates.(81, 82) While the toxicity study is mainly conducted 





models and vertebrate animal models, the extended fish embryo test (FET) 
using zebrafish is applied.(83) In this study, toxicity of lethal 
triphenylphosphine monosulfonate (TPPMS) capped 1.4 nm AuNPs was 
reduced largely after addition of glutathione, which is due to replacement of 
capping ligand on the AuNP surface. Note that in the same study it also shows 
different toxicity compared with HeLa cells study conducted by the same 
group.(83)  
However, there are some exceptions which are of great interest. As 
described above, a large number of toxicological studies are in vitro methods 
using immortalized cell lines, which may not provide information concerning 
biological barrier penetration, organ and/or cell specificity, embryonic 
development and subsequent differentiation. Another issue is that animal 
studies conducted using either zebrafish model or small rodent model make 
it hard to compare with human body. Instead of using cancerous cell lines, 
mouse embryonic stem cells are used to assess embryotoxicity in several 
experiments (85, 86), even more, a research of first use of human embryonic 
stem cells (hESCs) for embryotoxicity and neurotoxicity test has been 





normal cell lines, but also because of its pluripotency makes it extremely 
important to help determine the effects of AuNPs on differentiation process 
as well as on the differentiated neural progenitor cells (NPCs). Size-
dependent cytotoxicity was observed when inducing AuNPs in 1.5nm, 4nm, 
and 14nm with coating of thiolate capping ligands, 1.5nm AuNPs is extremely 
toxic and killed most of the hESCs while 4nm- and 14nm-AuNPs showed 
nontoxic.(36) In the same study it also shows that when exposed to all three 
sizes of AuNPs under nontoxic dosage the in vitro differentiation potential 
would not be affected, however, during neural differentiation, 1.5nmAuNPs-
treated group showed smaller embryo bodies which suggested that AuNPs 
in this size may cause negative influence even at sublethal concentration. 
After inducing 1.5nm AuNPs, NPCs were almost dead after 3 days referring 
to further toxicity of small size AuNPs. Note that cell uptake analysis shows 
that AuNPs in 1.5nm cannot enter hESCs in a noticeable amount instead a 
large amount of accumulation in the feeder layer cells was found.(36) This 
indicates that uptake of AuNPs varies among different cell lines, and this 





CHAPTER 3 ENGINEERING OF GOLD NANOPARTICLES CAPABLE OF 
BYPASSING BLOOD-BRAIN BARRIER 
 This chapter is reproduced with permission from the Scientific 
reports 6 (2016): 25794. Yanhua Zhang, Janelle Buttry Walker, Zeljka Minic, 
Fangchao Liu, Harry Goshgarian, and Guangzhao Mao. "Transporter protein 
and drug-conjugated gold nanoparticles capable of bypassing the blood-
brain barrier." And the Journal of Spinal Cord Medicine, accepted on 3th 
January 2019. Fangchao Liu, Yanhua Zhang, Janelle L. Buttry Walker, 
Guangzhao Mao, and Harry G. Goshgarian. " Diaphragmatic Recovery in 
Rats with Cervical Spinal Cord Injury Induced by a Theophylline 
Nanoconjugate: Challenges for Clinical Use". 
 3.1 Introduction 
 The leading causes of death among persons with spinal cord injury (SCI) 
since 1973, according to the National SCI Database, are from pneumonia and 
septicemia due to damage to respiratory muscle function caused by SCI(87). 
The major therapeutic challenge in the treatment of respiratory dysfunction 
caused by SCI, similar to other neurological diseases, is the inability of many 





system for the brain and generally only permits diffusion of neutral, lipophilic, 
and low molecular weight (smaller than 400-600 Da) molecules into the 
central neuron system (CNS) from blood(88, 89). Wheat germ agglutinin 
(WGA) is a lectin recognized by N-acetylglucosamine and sialic acid located 
on most neuronal cell membranes(90, 91) . WGA, in a few studies, has been 
used to enhance intranasal delivery of peptides to the brain through the 
olfactory route due to its affinity to the olfactory mucosa(92, 93). However, 
to our knowledge, this is the first study to use wheat germ agglutinin-
horseradish peroxidase (WGA-HRP) as a targeting moiety to transport drug-
bound nanoconjugates of tens of nanometers in size exclusively to the 
phrenic motoneurons that control respiratory function, effectively bypassing 
the BBB. When injected into muscle, WGA bound conjugates undergo 
retrograde transport to the motoneuron cell bodies and is then 
transsynaptically transported to the pre-motor neurons(94, 95). We 
synthesized a three-part nanoconjugate consisting of WGA-HRP chemically 
bound to AuNPs, which were also chemically bound to drugs previously 
shown to induce recovery of the diaphragm paralyzed by SCI.  Following 





nanoconjugate engages in receptor-mediated endocytosis resulting in 
retrograde transport of the nanoconjugate within motoneurons to the 
phrenic nuclei in the cervical spinal cord and transsynaptically to the rostral 
ventral respiratory groups (rVRGs) in the medulla. The drug, 1,3-
dimethylxanthine (theophylline or THP), is an adenosine receptor antagonist 
clinically used for the treatment of respiratory dysfunctions such as asthma, 
bronchitis, and respiratory muscle paralysis resulted from SCI(96-98). In rats 
with a spinal cord hemisection at the second cervical spinal segment (C2Hx), 
systemic (oral or intravenous) administration of THP or another adenosine 
receptor antagonist,  1,3-dipropyl-8-cyclopentylxanthine (DPCPX), resulted 
in an increase in respiratory output and recovery of the respiratory related 
activity by stimulating the crossed phrenic pathway (CPP)(97, 98). The CPP is 
a latent pathway, which crosses the midline below the level of SCI injury to 
synapse on the ipsilateral phrenic nuclei (PN) in the 3rd through 6th segments 
of the cervical spinal cord while the primary descending pathway, between 
the neuronal connection from the rVRG in the medulla to the ipsilateral 
phrenic nucleus, has been severed by a high cervical SCI(94). However, in 





effects including nausea and seizures(99, 100). These side effects are 
associated with nonspecific biodistribution and neuronal hyperactivity 
induced by the drug. Therefore, we designed a nanoconjugate in which the 
drug and the transporter protein are chemically linked through a 
nanoparticle carrier, the AuNPs, in order to reduce side effects of the drug 
by delivering it selectively to the respiratory neurons in the cervical spinal 
cord and medulla. A biodegradable bond between the drug and the 
nanoparticle carrier enables drug release at the targeted sites. The 
effectiveness of the nanoconjugate drug delivery was verified by the return 
of diaphragm muscle function previously paralyzed due to SCI.  AuNPs were 
selected as the drug carrier due to their biocompatibility, tunable colloidal 
chemistry, and quality control through a wide range of analytical 
methods(101, 102). 
 3.2 Experimental methods 
 3.2.1 Materials 
 Chemicals used in the following experiments: gold(III) chloride 
trihydrate (HAuCl4∙3H2O, 99% metal trace); sodium citrate tribasic dehydrate 





4-dimethylaminopyridine (DMAP, 99%); dimethyl sulfoxide (DMSO, 99.8%); 
37% formaldehyde solution; tetrahydrofuran (THF, 99%); N-
hydroxysuccinimide (NHS, 98%); dipropylcyclopentylxanthine (DPCPX, 97%); 
theophylline (THP, 97%) triethylamine (Et3N, 99%); lectin from triticum 
vulgaris (WGA-HRP) (Sigma-Aldrich, St. Louis, MO); 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC, 98%) (Sigma-Aldrich, St. Louis, 
MO). 
3.2.2 Nanoconjugate Synthesis and characterization 
The detailed synthesis of the nanoconjugate (WGA-HRP-AuNP-proTHP) 
has been published elsewhere (103). Briefly, to link theophylline to the AuNP 
via an ester bond, a hydroxymethyl group was added to theophylline creating 
7-(hydroxymethyl) theophylline or “proTHP”, using the Mannich reaction 
(103, 104). The reaction product was analyzed by proton nuclear magnetic 
resonance (1H NMR) to verify the formation of proTHP. Gold chloride (HAuCl4) 
was reacted with tri-sodium citrate to synthesize AuNPs. Mercaptosuccinic 
acid (MSA) was added as the capping ligand for the AuNPs. Then proTHP was 
attached to the MSA-capped AuNPs via a biodegradable ester bond to enable 





via an amide bond (106). Each step of the synthesis was verified by UV-vis 
spectroscopy, transmission electron microscopy, dynamic light scattering, 
and thermogravimetric analysis (TGA). Due to the instability of the 
synthesized proTHP, proTHP was stored in argon to prevent hydrolysis of the 
hydroxymethyl group by moisture in room air. In addition, to limit variation 
due to the biodegradable nature of the ester bond linking the AuNP to 7-
(hydroxymethyl) theophylline, the final solutions were only used up to 30 
days after synthesis. 
A variation of the nanoconjugate synthesized with hydroxyethyl 
theophylline (Sigma-Aldrich) in place of the 7-(hydroxymethyl) theophylline 
was also produced. The hydroxyethyl theophylline variation was tested to 
determine if the ester bond between theophylline and AuNPs could be 
further stabilized. 
UV-vis absorption spectroscopy (Varian Cary 50) was used to 
determine the AuNP size based on the Beer-Lambert law. The scan range was 
200–800 nm. 
The transmission electron microscope (TEM) images were taken on a 





droplet of the nanoconjugate solution on a Formvar-coated copper TEM grid. 
Excess liquid was removed by filter paper under the grid and the sample was 
air-dried. The working voltage was 200 keV and the current was 109 mA. For 
each image, 30 particles were randomly selected and measured to give the 
nanoparticle size distributions. 
The nanoparticle size was determined by dynamic light scattering (DLS) 
(Zetasizer Nano ZS, Malvern). A one ml solution of nanoparticle in PBS buffer 
was placed in a 2.0 ml polystyrene cuvette. The backscattering angle Θ was 
fixed at 180° with a laser wavelength λ = 633 nm. The size measurement 
range was set between 1 nm and 6 μm. The electrophoretic mobility of the 
nanoparticles was measured using the laser Doppler velocimetry and phase 
analysis light scattering technique of the Malvern Zetasizer. The 
electrophoretic mobility was converted into a zeta potential using the 
Smoluchowski equation using the Malvern software. 
TGA analysis was used to quantify the chemical composition of the 
nanoconjugate. TGA was performed on the SDT-Q-600 instrument using air 
as the working gas. The temperature range was 100–800 °C with a heating 





The LDI-MS measurements were carried out on a Bruker 
UltrafleXtreme MALDI-TOF/TOF Mass Spectrometer (Lumigen Instrument 
Center, Detroit). The samples were analyzed by LDI-MS after being 
transferred onto a MALDI target for LDI-MS analysis without adding any 
organic matrix. All mass spectra were acquired in the reflection mode and 
represent an average of 500 laser shots at a repetition frequency at 500 Hz. 
The accelerating voltage was set to 20 kV. The laser power was optimized in 
the range of 70–90% for each sample. The Bruker software flexAnalysis 







Figure 3-1 Synthesis schematic of transporter protein WGA-HRP and drug 
THP conjugated to the AuNPs. 
 
3.2.3 C2 Hemisection Surgery 
All animal studies were approved by the Wayne State University 
School of Medicine Institutional Animal Care and Use Committee.  In addition, 
all experiments were carried out in accordance with the Code of Ethics of the 
World Medical Association for experiments involving animals. Adult male 
Sprague Dawley rats were used in these studies (N=123). The rats were 
injected with atropine sulfate (0.04 mg/kg, im) 10 min prior to anesthesia 
induction to reduce mucus secretions during the subsequent aseptic survival 





ip) and xylazine (7 mg/kg, ip). After anesthesia induction, bupivacaine (2 
mg/kg, sc), a local anesthetic, was injected into the dorsal neck. The neck was 
then shaved and prepared for aseptic surgery. A left C2Hx surgical procedure 
was carried out as previously described (94). The dorsal neck muscles were 
closed using 4–0 absorbable sutures (Vicryl) followed by wound clips (Reflex® 
9 mm) for the skin. 
3.2.4 Electromyography (EMG) Analysis 
In all rats, immediately after C2Hx, paralysis of the ipsilateral 
hemidiaphragm was confirmed by EMG analysis. The previous study by 
Moreno and colleagues (94) correlated the loss of EMG activity in the 
ipsilateral hemidiaphragm to the lesion extent damaging the ipsilateral 
lateral and ventral funiculi of the cervical spinal cord where the descending 
respiratory drive is located, which was used here to ensure a complete 
hemisection (94). The abdominal surface of the diaphragm was exposed by 
a 6–8 cm horizontal incision made approximately 0.5 cm caudal and parallel 
to the costal margin. Bipolar platinum wire electrodes (Grass F-E2) were 
placed in each side of the diaphragm. Signals were amplified (20,000×) and 





Med, Inc., West Warwick, RI) and raw EMG signals were recorded by a 
Cambridge Electronic Design (CED, Cambridge, England) data acquisition 
system integrated with CED Spike 2® software. Recordings were taken from 
three areas of the left hemidiaphragm: anterior (sternal), lateral (costal) and 
posterior (crural). C2Hx rats that showed a complete absence of activity in 
all three areas and could produce an augmented breath were included in the 
study. An augmented breath is a confirmation that the CPP is intact and 
functional (94, 107).  
To observe the course of effect of theophylline following 
nanoconjugate injection subsequent EMGs were sampled from day 2 post 
injection up to and including day 14. Each rat underwent at minimum 1 EMG 
and no more than 3 separate EMGs with a minimum of 1 day between 
surgeries. The days selected for EMG were determined based on the time 
course for each rat and how many surgeries had already occurred; days 2 
through 7 each had a minimum of 7 rats used for data on each day. 
Subsequent EMG recordings were performed under ketamine/xylazine 
anesthesia while spontaneously breathing.  





Following EMG confirmation of hemidiaphragm paralysis immediately 
after the C2Hx, intradiaphragmatic injections were administered. Groups 
received injections based on their weight of one of the following solutions; i) 
nanoconjugate (WGA-HRP-AuNP-proTHP) 0.0005 mg/kg N=3, ii) 
nanoconjugate 0.0008 mg/kg N=4, iii) nanoconjugate 0.0025 mg/kg N=4, iv) 
nanoconjugate 0.005 mg/kg N=7, v) nanoconjugate 0.0075 mg/kg N=7, vi) 
nanoconjugate 0.01 mg/kg N=6, vii) nanoconjugate 0.03 mg/kg N=19, viii) 
nanoconjugate 0.07 mg/kg N=25, ix) nanoconjugate 0.12 mg/kg N=23, x) 
WGA-HRP-AuNP N=6, xi) AuNP-proTHP 0.07 mg/kg N=8. Investigation of the 
hydroxyethyl theophylline nanoconjugate consisted of 2 groups; 0.002 
mg/kg N=5, and 0.3 mg/kg N=6. Injections (10µl maximum volume per 
injection site) were spread equally from the posterior to anterior areas of the 
diaphragm using a Hamilton syringe. The needle was inserted parallel to the 
muscle fibers such that the tip of the needle was visualized by eye before 
administration of the injections, the needle was held in place for 5–10 
seconds before it was slowly withdrawn from the muscle to prevent 
leakage(108). 





Incisions were cleaned and the rats were given yohimbine (2mg/kg, ip) 
to reverse the xylazine, and buprenorphine (0.01mg/kg, sc) in 10mL saline 
for pain management. The rats were recovered on a heating blanket in a 
supine position to limit pressure on the diaphragm. Once rats could 
ambulate, they were returned to clean soft litter-lined cages with food and 
water provided ad libitum on the floor of the cage. The rats were also given 
cereal (Fruit-Loops®) as an enticement to eat. For the following 48-hours 
post-operative period, injections of buprenorphine (0.01mg/kg, sc) were 
given every 8-12 hours for pain management. Rats survived for 3, 7, or 14 
days’ post injection depending on the timeline for each experimental group. 
3.2.7 Immunohistochemical Visualization of Nanoconjugate 
72 hours after intradiaphragmatic injection of the nanoconjugate 
0.12mg/kg (N=3) into the left hemidiaphragm, rats were euthanized and 
underwent transcranial perfusion using heparinized saline followed by 4% 
formaldehyde (Fisher, F-79) (108). The cervical spinal cord (C3-C6) and 
medulla were removed and post fixed in 4% formaldehyde for 24 hours 
followed by 72 hours in 30% sucrose for cryoprotection. Tissues sections 50 





Tissue sections containing the phrenic nuclei and rVRGs underwent the 
immunohistochemistry protocol as described by Minic et al. (108); sections 
were washed three times in the immuno-buffer (PBS with 0.3% Triton) and 
then blocked using 10% normal horse serum (Invitrogen) in the immuno-
buffer. Sections were incubated in primary antibody goat anti-WGA (1:200, 
AS-2024, Vector Laboratories), diluted in 10% normal horse serum immuno-
buffer solution for 72 h, and then washed in PBS. Sections were then 
incubated in the biotinylated secondary antibody, donkey anti-goat 
overnight (1:400, Jackson Immuno Research Laboratories). Sections were 
then incubated in streptavidin-tagged-Cy3 for 4 h and then mounted wet on 
the slides and coverslip. Tissue sections were examined on a Zeiss 
Axioimager.M2 fluorescent microscope. Images were captured using the Zen 
2 pro Blue edition program. Off-line processing was used to acquire high-
power views of the phrenic nuclei and the rVRGs. 
3.2.8 Phrenic Nerve Recordings 
Bilateral phrenic nerve recordings were sampled at day 3, 7, and 14 
under standardized conditions. The rats were injected with atropine sulfate 





secretions during the procedure. The anesthesia was a mixture of ketamine 
(70mg/kg, ip) and xylazine (7mg/kg, ip), a supplement was provided as 
needed. Phrenic nerves were accessed from the ventral surface of the neck 
and cut distally to eliminate afferent activity. Each nerve was positioned on 
platinum bipolar electrodes and coated with mineral oil to prevent fluid 
interference with the signal and to reduce electrical noise. Before acquiring 
nerve activity data, the following standardizing conditions were performed: 
(1) animals were bilaterally vagotomized; (2) animals were paralyzed using 
pancuronium bromide (0.5 mg/kg, iv); and (3) animals were placed on a 
ventilator set at 3–5mmHg above the apnea threshold (108). The procedure 
for determining the apnea threshold has been described previously (109). 
The unprocessed recording was amplified 5000 times using Grass P511 
amplifiers (Grass Technologies), filtered at 0.3–1 kHz. The recordings were 
digitized, rectified, and integrated in 0.1 s intervals using the Cambridge 
Electronic Design data acquisition system and the Spike 2 software. 
3.2.9 Statistical Analysis 
As described by Minic et al. (108), EMG analysis was intended to only 





Treatment groups were divided into a “Yes” or “No” category based on the 
following criteria described by Minic et al. (108); Recovery of the left 
hemidiaphragm was considered positive/Yes in each rat only if the following 
conditions were met: (1) the EMG activity was detected in at least two of the 
three diaphragm areas (posterior, lateral, or anterior); and (2) if the activity 
persisted for the duration of the study. In each treatment group, rats were 
then divided into those having recovery or not, and the Fisher exact test was 
performed to determine whether the proportion of rats with an incidence of 
recovery in the treated groups was statistically different from the ratio of 
control animals with an incidence of recovery. The Fisher’s exact test was 
followed by the Bonferonni adjustment to correct for the number of 
comparisons tested. A α level of 0.016 was considered statistically significant 
(SigmaPlot 13.0). Groups that demonstrated a significantly higher incidence 
of recovery during the initial screening process, to determine optimal drug 
dose, were further investigated using phrenic nerve recordings to quantify 
recovery observed. 
Terminal bilateral phrenic nerve recordings were used to estimate the 





by Minic et al. (108). The areas under 10 consecutive integrated waveforms 
(INT) in the right phrenic nerve (RPN) and left phrenic nerve (LPN) activity 
were averaged and expressed as mean ±SE. Activity of the LPN was used as 
an index of the recovered respiratory activity in the THP nanoconjugate-
treated rats. Both maximum (MAX) LPN amplitude activities as well as the 
areas under the curves (AUC) were expressed as the percentage of the RPN 
whose signal was set to be 100%. Then the average % INT and the average % 
MAX for each group was averaged and subjected to statistical examination 
using SigmaPlot 13.0. All groups underwent One-way ANOVA followed by 
Holm-Sidak pairwise comparison to determine the effect of the injected 
solution. A α level of 0.05 was considered statistically significant. 
3.3 Results 
3.3.1 Characterizations of AuNP conjugates 
 The nanoconjugates from each stage of synthesis were characterized 
by UV-vis spectroscopy, transmission electron microscopy (TEM), dynamic 
light scattering (DLS), and thermogravimetric analysis (TGA). Figure 3.2A 
shows the UV-vis spectra of MSA-capped AuNP, AuNP-pro-THP, and WGA-





temperature. The UV-vis spectra of a constant absorption peak at 508-510 
nm are in the expected range for AuNPs with 4 nm core diameter and they 
also indicate a high degree of colloidal dispersion stability at all stages of the 
synthesis. Figure 3.2B-D show TEM images of MSA-capped AuNPs, AuNP-
pro-THP, and WGA-HRP-AuNP-pro-THP. The particle size histograms of 
which are shown in Figure 3.2E-G, respectively. The AuNPs were well 
dispersed and the diameter of the AuNPs remained unchanged at 4.1 ± 0.3 
nm before and after conjugation with pro-THP according to TEM. The AuNPs 
size increased slightly to 5.2 ± 1.3 nm. Here, there is uncertainty in particle 
core size determination due to the conjugated WGA-HRP and overlapping 
particles. Particle agglomeration, observed in WGA-HRP-AuNP-pro-THP 






Figure 3-2 Characterization of transporter protein and drug-conjugated 
AuNPs. A) UV-vis spectra measured at room temperature. B-D) TEM images 
of AuNP conjugates. E-G) Sized distributions of AuNP conjugates 
 
The zetasizer provided measurements of the particle hydrodynamic 





diameters are 4.8 nm (zeta potential = -28.5 mV) for MSA-capped AuNP, 11.7 
nm (zeta potential = -36.6 mV) for AuNP-pro-THP, and 37.8 nm (zeta 
potential = -35.6 mV) for WGA-HRP-AuNP-pro-THP. The zeta potential 
measurements were conducted in PBS buffer (pH = 7.4) at 37C. The 
hydrodynamic size of different nanoconjugates are shown in Figure 3.3. The 
size increase after each conjugation reaction is consistent of successful 
coupling of the drug or protein to the AuNP. The negative surface charge 
characteristic of all the nanoparticles provides the necessary electrostatic 
repulsion to ensure aqueous dispersion stability of the nanoparticles. 
 
Figure 3-3 Zetasizer measurements of A) pro-THP nanoconjugates and B) 
pro-DPCPX nanoconjugates. All samples were measured in PBS buffer 
(pH=7.4) at 37°C. 
 
The chemical compositions of the intermediate and final 





percentages of weight losses at different stages of synthesis, we were able 
to estimate that in the final nanoconjugate, there are 204 pro-THP molecules 
conjugated to one 4 nm MSA-capped AuNP and 2 MSA-capped AuNPs 
conjugated to one WGA-HRP. The numbers of drug molecules conjugated 
correspond to 60% occupation for pro-THP of all available carboxyl provided 
by MSA. The detailed calculations can be found in the SI 1.3. We observed 
that the number of conjugated drug molecules remained unchanged with 
increasing drug to Au molar feed ratio in the reaction indicating that a 
surface saturation was reached possibly due to a steric effect. It is interesting 
to note that in both THP (Figure 3.4A) and DPCPX (Figure 3.4B) cases we 
obtained similar protein to AuNP molar ratio of 1 to 2. This nanostructure 






Figure 3-4 TGA data of weight loss for A)MSA-AuNPs, AuNP-pro-THP, and 
WGA-HRP-AuNP-pro-THP; B) MSA-AuNPs, AuNP-proDPCPX, and WGA-HRP-
AuNP-pro-DPCPX. 
 
Calculations of nanoconjugate drug and protein loading amounts 
based on TGA and TEM results are shown below.  
The weight of one molar AuNP (W) with a diameter (D = 4 nm based 
on the TEM measurements) was estimated using the following formula using 













The molecular weight of MSA (C4H6O4S) and pro-THP are 150 g/mol 





corresponds to 171 MSA molecules per AuNP as calculated below. As a result, 
























The weight loss of 15.0% (AuNP: MSA: pro-THP = 100: 6.6: 11.1) shows 













This means that 60% of all possible reactive sites provided by MSA are 
occupied by pro-THP. 
The total weight loss for the three-part nanoconjugate is 21.6% (AuNP: 
MSA: pro-THP: WGA-HRP = 100: 6.6: 11.1: 11.5) indicates that each WGA-
















For pro-DPCPX drug (TGA spectra shown in Supplementary Fig. 3), the 
weight loss of 12.9% (AuNP: MSA: pro-DPCPX = 100: 6.6: 8.2) corresponds to 
96 pro-DPCPX molecules conjugated to one MSA-capped AuNP. This means 













The total weight loss for the three-part nanoconjugate is 21.0% (AuNP: MSA: 
pro-DPCPX: WGA-HRP = 100: 6.6: 8.2: 11.8) indicates that each WGA-HRP is 













 Three rats underwent intradiaphragmatic injections of the 
nanoconjugate following a C2Hx to visualize the locations of the 
nanoconjugate. An immunohistochemical technique was utilized to visualize 
the WGA component of the nanoconjugate. The WGA-HRP-AuNP bond is a 
relatively long-lasting amide bond whereas the AuNP-proTHP bond is a 





should also identify where the AuNPs are but not necessarily the proTHP. All 
3 rats produced identical results verifying what was reported in (103). WGA 
positive label was identified in the ipsilateral PN in the cervical spinal cord 
and bilaterally in the rVRGs in the medulla (Figure 3.5). The bilateral rVRGs 
labeling was notably less intense compared to the label in the PN. These 
results suggest that at minimum, the WGA-HRP-AuNP portion of the 
nanoconjugate is capable of being transported to the PN and subsequently 










Figure 3-5 WGA identified in the phrenic nuclei in the cervical spinal cord 
and rostral ventral respiratory groups in the medulla 72 hours after 
intradiaphragmatic injection. Scale bar is 50 μm. P (in A and E) notes 
pinhole to mark side contralateral to the injection. 
 
3.3.3 Electromyography (EMG) 
Based on the criteria described by Minic et al. (108), results from EMG 
analysis were used as a Yes/No screening tool to determine which doses 
should undergo further analysis using the phrenic nerve recording technique. 
Starting with the lowest tested dose, functional recovery of the diaphragm 
after a one-time injection of the nanoconjugate dose 0.0005mg/kg was 
detected in 66% of the rats (N=3). Diaphragm activity was detected as early 
as day 3 and persisted to day 14, the longest time point tested. However, the 
duration of the burst was less than the non-injured side. Therefore, in each 
subsequent group, the dose was incrementally increased to find an optimal 
therapeutic dose. 
The doses 0.0008mg/kg and 0.0025mg/kg both resulted in a return of 
diaphragm activity that occurred in 50% of the rats (N=4 and N=4, 
respectively). Both doses resulted in diaphragm recovery lasting the full 14 





recovery in only 0.14% of the rats (N=7 and N=7, respectively) and the dose 
0.01mg/kg resulted in no observable recovery (N=6). 
When the dose was increased to 0.03mg/kg recovery was observed in 
63% of the rats (N=19). Similarly, the dose 0.07mg/kg, resulted in the 
incidence of recovery as early as day 2 post nanoconjugate injection and 
lasted up to day 14 in 56% of the rats (N=25) (Figure 3.6), and the 0.12mg/kg 
dose resulted in the incidence of recovery in 45% of the rats (N=20). 
Interestingly, in 3 rats from the 0.12mg/kg dose group the LHD burst 
frequency was minimal but sporadic and sometimes off rhythm compared to 
the right side, a possible effect of over stimulation (97). Thus, we did not go 
beyond the 0.12mg/kg dose in this study.  
Injection of a control solution containing a conjugate of just AuNP-
proTHP 0.07mg/kg (no WGA-HRP) (N=8), or WGA-HRP-AuNP (no proTHP) 
(N=6) never produced recovery of the LHD. 
Investigation of the hydroxyethyl theophylline nanoconjugate 
consisted of 2 groups; 0.002 mg/kg N=5, and 0.3 mg/kg N=6. The group that 





received 0.3 mg/kg had a 33% occurrence of recovery, however the bursting 
patterns were sporadic in respect to the pattern produced by the RHD. 
 
Figure 3-6 EMG traces 2 days and 14 days post injection 0.7 mg/kg 
nanoconjugate. Both recordings were obtained from the same rat. A) 2 days 
post injection of the dose 0.07mg/kg nanoconjugate there is a return of the 
bursting pattern in the left hemidiaphragm (top trace). The bursts in the left 
hemidiaphragm match those in the right hemidiaphragm (bottom trace). B) 
14 days post injection; the activity has persisted in the left hemidiaphragm 
(top trace) and remains synchronous with the right hemidiaphragm (bottom 
trace). In both traces an augmented breath is demonstrated (arrows) 
followed by a short period of apnea. The augmented breath shows the 






Statistical significance of the incidence of functional recovery detected 
with the EMG analysis was determined using the Chi Square-Fisher’s exact 
test followed by the Bonferroni adjustment (Figure 3.7). Treatment with 
0.03mg/kg, 0.07mg/kg, or 0.12mg/kg of the nanoconjugate via 
intradiaphragmatic injection resulted in a significantly greater proportion of 
rats achieving functional recovery when compared to the control 0.07mg/kg 
AuNP-proTHP; p=0.003, p= 0.010, p=0.029 respectively. Treatment with 
0.03mg/kg or 0.07mg/kg of the nanoconjugate resulted in a significantly 
greater proportion of rats achieving functional recovery when compared to 
the dose 0.01mg/kg; p=0.015, p=0.021 respectively.  In addition, treatment 
with 0.03mg/kg or 0.07mg/kg of the nanoconjugate resulted in a significantly 
greater proportion of rats achieving functional recovery when compared to 
the control WGA-HRP-AuNP; p=0.015, p=0.021 respectively. However, with 
lone EMG data it is unclear as to whether this is isolated muscle activity 
stimulated by the injection containing proTHP (110-115), or if it is a return of 






Figure 3-7 Percent of Rats with EMG Recovery of the Left Hemidiaphragm. 
The chart displays the percentage of rats in each group that had an incidence 
of recovery detected by EMG of the left hemidiaphragm. Statistical analysis 
consisted of data from 112 rats. A Chi-square test was performed, and 
significance was found between the proportions of observations (Yes/No) 
and the groups, X2 (13, N = 112) = 27.075, p = 0.012. Treatment with the 
0.03mg/kg nanoconjugate resulted in significantly greater (#) incidence of 
recovery compared to 0.01mg/kg (P = 0.015); WGA-HRP-AuNP (P = 0.015); 
and 0.07mg/kg AuNP-proTHP (P=0.003). Treatment with the 0.07mg/kg 





compared to 0.01mg/kg (P = 0.021); WGA-HRP-AuNP (P = 0.021); and 
0.07mg/kg AuNP-proTHP (P = 0.010). Treatment with the 0.12mg/kg 
nanoconjugate resulted in significantly greater (‡) incidence of recovery 
compared to 0.07mg/kg AuNP-proTHP (P = 0.029). 
 
3.3.4 Phrenic nerve recordings 
Based on the screening data obtained from the EMG analysis the doses 
0.03, .0.7, and 0.12mg/kg were selected to analyze the amount of recovery 
based on the output of the phrenic nerves at days 3, 7, and 14. A 
representative recording from each day. The nanoconjugate induced 
recovery was quantified by analyzing 10 consecutive breaths from bilateral 
phrenic nerve recordings sampled at days 3, 7, and 14. Controls solutions 
were sampled on day 7. The area under the curve (AUC) from the right and 
left integrated (INT) waveforms were calculated and the percent recovery of 
the left compared to the right was calculated for both the INT and maximal 
amplitude (MAX). The data used in the following statistical analysis was 
obtained once physiologically standardized conditions were established (108, 
109, 116-119). One-way ANOVA with Holm-Sidak pairwise comparison was 
performed to determine the effect of the nanoconjugate or control solution 





One-way ANOVA showed a significant drug effect on day 3 between 
the 0.12mg/kg dose and the remaining two groups, 0.03mg/kg dose and 
0.07mg/kg dose for the AUC (p<0.001) but not the MAX (Figure 3.8).  
One-way ANOVA showed a significant drug effect on day 7 for the AUC 
between the 0.07mg/kg dose and the following; 0.03mg/kg (p<0.001), 
0.12mg/kg (p<0.001), WGA-HRP-AuNP (p<0.001), 0.07mg/kg AuNP-ProTHP 
(p<0.001). There was significant drug effect for the MAX between the 
0.07mg/kg dose and the following; 0.03mg/kg (p=0.013), WGA-HRP-AuNP 
(p=0.027), 0.07mg/kg AuNP-ProTHP (p=0.013) (Figure 3.9). Interestingly all 
control solutions at day 7 resulted in detectable recovery of the phrenic 
nerve, however the level of recovery of the LPN in several groups was 
negligible. 
One-way ANOVA showed a significant drug effect on day 14 for the AUC 
between the 0.03mg/kg dose and the 0.12mg/kg dose (p=0.030). There was 
also a significant drug effect for the MAX between the 0.03mg/kg dose and 







Figure 3-8 Day 3 Phrenic Nerve Recordings Analysis. The average percent 
integrated (AUC) and average percent maximum amplitude (MAX) of the LPN 
compared to the RPN. Statistical data consisted of neurograms from 18 rats. 
One way ANOVA showed significant drug effect (#) on day 3 between the 
0.12mg/kg dose group and the remaining two groups, 0.03mg/kg dose and 








Figure 3-9 Day 7 Phrenic Nerve Recordings Analysis. The average percent 
integrated (AUC) and average percent maximum amplitude (MAX) of the LPN 
compared to the RPN. Statistical data consisted of neurograms from 18 rats. 
One way ANOVA showed significant drug effect on day 7 for the AUC 
between the 0.07mg/kg dose and the following; 0.03mg/kg (p<0.001), 
0.12mg/kg (p<0.001), WGA-HRP-AuNP (p<0.001), 0.07mg/kg AuNP-ProTHP 
(p<0.001). There was significant drug effect for the MAX between the 
0.07mg/kg dose and the following; 0.03mg/kg (p=0.013, *), WGA-HRP-AuNP 







Figure 3- 10 Day 14 Phrenic Nerve Recordings Analysis. The average percent 
integrated (AUC) and average percent maximum amplitude (MAX) of the LPN 
compared to the RPN. Statistical data consisted of neurograms from 18 rats. 
One way ANOVA showed significant drug effect (#) on day 14 for the AUC 
between the 0.03mg/kg dose and the 0.12mg/kg dose (p=0.030). There was 
also significant drug effect (†) for the MAX between the 0.03mg/kg dose and 
the remaining two doses 0.12mg/kg (p=0.001) and 0.07mg/kg (p=0.049). 
 
Based on statistical analysis of the neurograms, each dose had a 
significant drug effect for the three different time points; 0.12mg/kg on day 





tested that produced consistently significant recovery for all time points 
compared to the remaining doses. These data may reflect the inconsistent 
synthesis of the theophylline nanoconjugate. 
 
3.4 Discussions 
The WGA component of the nanoconjugate was identified by 
immunostaining in all three rats in the ipsilateral PN in the cervical spinal 
cord and bilaterally in the rVRGs in the medulla. This shows that the WGA-
HRP component of the nanoconjugate was transported to the phrenic 
nucleus and transsynaptically to the rVRG. However, this technique does not 
confirm if theophylline is also located in the PN and rVRGs, which must occur 
for the theophylline to stimulate the CPP. This is due to the hydrolysable 
ester bond that enables the detachment of theophylline from the 
nanoparticle carrier. The primary drug release from ester-based drug linkers 
on nanomaterials is due to intracellular action of acid hydrolases in the acid 
compartments such as endosomes (pH 5.0-6.0) and lysosomes (pH 4.8). (120) 
Drug release from ester linkage to nanomaterials tends to be rather slow. For 





a dendrimer carrier in a serum medium at 37ºC. (121) In another study, less 
than 5% of an antitumor drug SN38, a metabolite of irinotecan, released 
from its nanocarrier after 24 h in PBS buffer. (122) In a third study, the ester 
link of an immunosuppressive agent FK506 conjugated to dextran has a half-
life of ~150 hours in a phosphate buffer (pH = 7.4). (123) We are currently 
conducting in vivo experiments to determine the biodistribution of the 
nanoconjugate as well as in vitro experiments simulating the in vivo 
environments to quantify the theophylline release profile from the 
nanocarrier. 
The results from EMG analysis demonstrate that the nanoconjugate 
doses 0.0005, 0.0008, 0.0025, 0.03, 0.07, and 0.12mg/kg stimulate recovery 
of LHD activity detected as early as day 2 post injection and persisting up to 
14 days. Again, based on literature it is likely significant amount of 
theophylline is still attached to the nanocarrier at the time of detection of 
LHD activity. Although current techniques are unable to confirm the 
presence of theophylline in the PN and rVRGs in this study, we confirmed the 





appearing by day 2 post injection corresponds with the time required for the 
uptake of WGA to the PN and rVRGs (94). 
The control solutions, WGA-HRP-AuNP and 0.07mg/kg AuNP-proTHP 
did not produce LHD recovery in any of the rats tested. It is interesting to 
note that AuNP-proTHP was unable to produce LHD recovery even though 
proTHP was present. The explanation behind this remains unclear; however, 
without the WGA-HRP there is no transporter to initiate absorptive 
endocytosis at the phrenic nerve terminals following injection, therefore the 
drug should not have been delivered to the phrenic nuclei and rVRGs. It is 
possible for the theophylline to be released in the muscle and have a 
systemic effect but the dose administered via the nanoconjugate is a fraction 
of that needed to stimulate CPP recovery following systemic administration 
(97). 
To better characterize the effect of the nanoconjugate, quantification 
of bilateral nerve recordings under standard conditions were compared 
between groups. The use of ketamine during a procedure to test for 
respiratory activity may appear problematic. However, in this study all 





detecting activity of the phrenic nerve on the non-injured side. Future, in the 
study by Giroux et al. (124), the effect of ketamine-xylazine anesthesia on 
respiration in SD rats was described. Rats used in the current study were 10-
14 weeks of age (approximately 3 months) selected based on their weight. 
The study by Giroux et al. (124), demonstrates that the concern of 
respiratory depression following ketamine-xylazine use in younger adult rats 
(3 months) is only of valid within the first 15-30 minutes after intraperitoneal 
administration. At the 45-minute time point Giroux et al. (124), found that 
respiratory frequency had returned to pre-dosing levels in rats 3 months of 
age. 
The variation of the AUC percent recovery observed for the 3 
nanoconjugate doses over the course of the study might demonstrate the 
drug dose effect on respiration as the drug is metabolized and lasting effects 
over time. For all timepoints tested the 0.03mg/kg dose produced the 
highest percent of LPN activity with an AUC of 2.2%, however this is modest 
LPN recovery at best. Fortunately, in addition to theophylline there are 
multiple drugs known to enhance respiration following high SCI including 





to this study AuNPs conjugated to WGA-HRP and DPCPX were being 
investigated (108). Injection of the DPCPX coupled nanoconjugate 
(0.15µg/kg DPCPX) produces an average percent recovery of 56.8% on day 7 
and 72.4% on day 14 for the AUC of the LPN compared to the right phrenic 
nerve (108). Further investigation into the use of the DPCPX nanoconjugate 
is underway.  
Throughout this work the chemical stability of the theophylline 
nanoconjugate for in vivo application became apparent. To chemically link 
theophylline to the AuNPs, a hydroxymethyl group was added to the 
theophylline creating proTHP, which then forms an ester bond with the 
capping agent, MSA, on the AuNPs following the Steglich reaction. The 
synthesized ProTHP was originally stored in vials in ambient air. We 
discovered that proTHP is reactive to moisture and hydrolyzes back to THP. 
When comparing 2 nanoconjugate batches (not used in the study), 
thermogravimetric analysis (TGA) detected a 5.7% weight variance, which is 
the difference of 105 molecules of proTHP attached to each AuNP. The 
hydrolysis tendency of proTHP poses significant challenges for the long-term 





apparent instability of proTHP we developed an experimental protocol to 
characterize the drug concentration for every batch with TGA to verify 
uniformity before in vivo use. The integrity of bond stability has been 
emphasized by others (126). It was decided to limit the use of the 
nanoconjugate for no longer than 30 days post synthesis. To further protect 
proTHP from hydrolysis we stored the newly synthesized proTHP in argon 
gas. We suggest that further investigation into the effects of the proTHP-
bound nanoconjugate should take proTHP hydrolysis into consideration and 
carefully quantify the nanoconjugate chemical composition. Interestingly 
WGA-HRP-AuNP-DPCPX nanoconjugate used in the Minic et al. (108) study 
did not encounter the same issues stated above. In comparison to 
theophylline, DPCPX is more hydrophobic with an additional 5-carbon ring, a 
characteristic that may contribute to the chemical stability of pro-DPCPX 
against hydrolysis.  
To increase the stability of the AuNP-proTHP bond, an alternative chemical 
bond was investigated. The nanoconjugate used in the work described 
herein used a methyl-binding site; we later identified a version of the proTHP 





change in the binding site resulted in less proTHP molecules bound per AuNP 
requiring a higher AuNP concentration to maintain the same drug dosage. 
The effectiveness of the proTHP-coupled nanoconjugate via an ethyl bond 
was less than the methyl bond. Therefore, efforts to further investigate the 
ethyl version were abandoned due to low effectiveness.   
There were notable differences in the AuNP concentration between 
solutions. To deliver an effective dose of proTHP, the AuNPs in solution were 
at a concentration of 0.8 mg Au/ml, but at this concentration, we noticed 
some degree of aggregation of the AuNPs. Nanoparticle aggregation in 
biological milieu occurs frequently and this limits nanoconjugate uptake by 
cells (e.g., via endocytosis). The concern of aggregation became evident 
during an ongoing biodistribution study, while euthanizing rats that received 
injections 8 weeks prior, the black appearance of the AuNPs, indicative of 
AuNPs aggregation, was still visible in the diaphragm. If the AuNPs are still 
visible in the muscle 8 weeks’ post injection one must consider the likelihood 
of proTHP being delivered to the appropriate nuclei versus the proTHP bond 
degrading in the muscle. To explore this concern, the concentration of the 





determine if by lowering the AuNP concentration the probability of AuNP 
aggregation would be reduced and the probability of nanoconjugate uptake 
and proTHP delivery would increase. Reduction of the AuNP concentration 
in solution did result in a reduction of aggregation, as expected, which was 
confirmed visually by a color change from pinkish red to dark blue, however 
the effectiveness of proTHP failed to reach the level of recovery produced by 
the DPCPX-coupled nanoconjugate. Interestingly the therapeutic dose of 
DPCPX required only 0.1 mg Au/ml and therefore aggregation complications 
never arose during the DPCPX study.  
3.5 Conclusions 
WGA-HRP-AuNP-proTHP nanoconjugates are capable of significantly 
increasing the amount of LPN recovery when injected intradiaphragmatically 
immediately after C2Hx compared to the control treatments. Targeting 
delivery of theophylline reduces the therapeutic dose from 15mg/kg IV(97) 
to less than 0.2mg/kg. In doing so the restored left hemidiaphragm and left 
phrenic nerve function can be detected as early as 2 days and persists up to 
day 14 post injection. However, the WGA-HRP-AuNP-proTHP nanoconjugate 





administration of the WGA-HRP-AuNP-DPCPX nanoconjugate (108). The 
clinical use of theophylline in humans led us to expend maximum effort to 
find a combination of the proTHP coupled nanoconjugate to reach the 
effectiveness of the DPCPX coupled nanoconjugate. However, the proTHP 
nanoconjugate continued to present stability concerns both in terms of its 
chemical stability in storage and colloidal stability post injection. The amount 
of proTHP per AuNP for effective recovery requires an AuNP concentration 
that is prone to aggregation, which limits the transport and cellular uptake 
of the nanoconjugate. While it is possible to overcome these stability issues 
by investigating alternative chemical conjugate chemistry, our lab has 
already yielded a more promising nanoconjugate, DPCPX-containing 
nanoconjugate (108). The effectiveness of the DPCPX coupled 
nanoconjugate well-surpassed those of proTHP, therefore all our future 
efforts will be directed towards the DPCPX-coupled nanoconjugate.    
Lastly, the application of the WGA-HRP-AuNP nanoconjugate is not 
limited to the phrenic motor system. WGA-HRP has been applied over the 
decades to identify many neuromuscular pathways. In theory, injection of 





hold promise for investigation and treatment of multiple disease and injury 
models.  
 
CHAPTER 4 ANTI-CANCER DRUG CONJUGATED NANOPARTICLES INDUCED 
CELL DEATH IN TRIPLE NEGATIVE BREAST CANCER CELLS 
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The human homologues of yeast Rad6, HHR6A and HHR6B (referred 
as Rad6A and Rad6B) play a fundamental role in DNA damage tolerance 
pathway (127-130), and the ubiquitin conjugating activity of Rad6 is essential 
for this function (131). The Rad6B homologue is overexpressed in metastatic 
and chemo-resistant breast carcinomas (132-134). Constitutive 
overexpression of Rad6B in nontransformed human breast epithelial cells 
induces tumorigenesis and resistance to cisplatin and doxorubicin (132, 135, 
136). Conversely, Rad6B silencing renders cells chemo-sensitive (136), 
implicating the relevance of Rad6 in transformation and drug resistance, and 
the potential therapeutic benefit of inhibiting Rad6. We have recently 
reported the development of a novel Rad6-selective small molecule inhibitor 
SMI#9 that inhibits Rad6 ubiquitin conjugating activity (137). SMI#9 
treatment suppresses proliferation and migration and induces apoptosis in 
breast cancer cells but spares normal breast cells (137). However, SMI#9 has 
poor aqueous solubility that limits its therapeutic efficacy. Here we 






Gold nanoparticles (AuNPs) are ideal drug delivery scaffolds because 
they are nontoxic and nonimmunogenic (138, 139), and have good 
biocompatibility and stability (140). Surface modification allows AuNPs to be 
readily functionalized with multiple agents including chemotherapy, 
oligonucleotides and proteins making them good delivery vehicles (141). 
Several AuNP-based drugs have been developed by CytImmune with their 
lead drug Aurimune (TNF bearing PEGylated gold nanoparticles) in clinical 
trials. 
This chapter will describe the synthesis of SMI#9-tethered AuNPs 
using a chemistry that allows intracellular release of SMI#9. SMI#9-AuNPs 
were characterized for size and ligand conjugation, and intracellular release 
of conjugated SMI#9 by Fourier transform infrared spectroscopy (FTIR) and 
liquid chromatography coupled tandem mass spectrometry (LC-MS/MS). 
Intracellular uptake, localization, cytotoxicity and molecular responses to 
AuNP-conjugated SMI#9 were evaluated in triple negative breast cancer 
(TNBC) cells as TNBC represents a heterogeneous disease with poor clinical 
outcomes and few targeted therapy options as they lack estrogen receptor, 





responses to conjugated and free SMI#9 in two major subtypes of TNBC, 
mesenchymal and basal types (142) to authenticate the functionality of 
AuNP-tethered SMI#9. We show that the mesenchymal subtype is sensitive 
to SMI#9-AuNP and that modified SMI#9 released from AuNP acts similarly 
to unconjugated parent SMI#9. 
4.2 Experimental methods 
4.2.1 Materials 
Sodium bicarbonate (NaHCO3), di-tert-butyl dicarbonate ((Boc)2O), 37% 
formaldehyde (HCHO) solution, triethylamine (Et3N), tetrahydrofuran (THF), 
gold(III) chloride trihydrate (HAuCl4∙3H2O), sodium citrate tribasic dihydrate, 
mercaptosuccinic acid (MSA), sodium borohydride (NaBH4), dimethyl 
sulfoxide (DMSO), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-
hydroxysuccinimide (NHS), and 4-dimethylaminopyridine (DMAP) were 
purchased from Sigma-Aldrich. 
 4.2.2 Synthesis of gold nanoparticle (AuNP) and conjugation of Rad6 
inhibitor SMI#9 to AuNP 
 Mercaptosuccinic acid (MSA)-capped AuNP (MSA-AuNP) was 





was added with vigorous stirring to a solution of 0.25 mM HAuCl4∙3H2O and 
0.25 mM trisodium citrate. The pH was adjusted to 11, and 50 mg MSA was 
added. The final solution was concentrated to 2.5 g (gold)/L by centrifugation 
using 10,000 MW Amicon filters. SMI#9 was modified to enable AuNP 
conjugation via an ester bond. To modify SMI#9, 1.5 mg SMI#9 was dissolved 
in 0.5 ml tetrahydrofuran (THF; 50%, v/v) followed by addition of 10 mg of 
NaHCO3 and 2.6 mg di-tert-butyl dicarbonate (Boc)2O. After 30 min reaction, 
5 µl of HCHO and 5 µl of triethylamine (Et3N) were added and the 
hydroxymethylation reaction was allowed to proceed for 48 h. The solution 
was then added to AuNP (2.5 g/L gold concentration) solution. The pH of the 
solution was adjusted to 4.7 with MSA, and 2 mg 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), 0.2 mg 4-dimethylaminopyridine 
(DMAP), and 2 ml dimethyl sulfoxide (DMSO) were added to catalyze the 
esterification reaction. After 40 h, the final solution was concentrated to 0.2 
g mL-1 by centrifugation using 10,000 MW Amicon filters and desalted by 
exchanges with deionized water. 





 SMI#9 conjugated to AuNP was characterized by thermogravimetric 
analysis (TGA) on an SDT-Q600 Thermo-Gravity Analyser using air as the 
supporting gas. The air flow rate was maintained at 100 ml/min, and sample 
heated from 25 to 800 °C at a rate of 10 °C/min. AuNP “solutions” were also 
characterized by UV–vis spectroscopy with a Varian Cary® 50 spectrometer 
in 2 mm optical path cells, and by transmission electron microscopy (TEM) at 
200 kV with a JEOL JEM-2010 microscope equipped with a Gatan multiscan 
CCD camera. 
Dynamic light scattering (DLS) and zeta potential were measured using 
a Malvern Nano-ZS. The Z-average hydrodynamic diameter (HD), 
polydispersity index (PDI), and zeta potential were measured at 25 °C. 15 
scans were performed in each measurement. 
4.2.4 Cell lines and culture 
 MDA-MB-231 (BRCA1 wild-type) and MDA-MB-468 (BRCA1 wild-type) 
human TNBC cells were purchased from ATCC, and SUM1315 (BRCA1 mutant) 
TNBC cells were purchased from Asterand. All lines were maintained in 





bank (short tandem repeat PCR) and Mycoplasma screening (MycoAlert, 
Lonza), several aliquots of cells were frozen and used within 10 passages. 
 4.2.5 SMI#9 and SMI#9-AuNP uptake and intracellular release of the 
free drug from AuNP conjugate 
 MDA-MB-231 (3 × 105) cells were plated in 35 mm dishes and exposed 
to various doses of SMI#9-AuNP or untreated for 24-48 h. Cultures were 
rinsed, lysed by freeze–thaw cycles in cold hypotonic buffer, and clarified by 
centrifugation at 10,000g. Aliquots of clarified lysates were analyzed by FTIR 
spectroscopy using control lysates spiked with free SMI#9 as reference. To 
determine intracellular release of modified SMI#9 from nanoparticles, 
SUM1315 (2 × 106 cells/100 mm dish) cells were exposed for 8 or 24 h to 5 
μM free SMI#9, 5 μM SMI#9-AuNP or the corresponding amount of blank-
AuNP, or untreated. Cultures were rinsed in ice-cold phosphate buffered 
saline (PBS), lysed with cold 80% methanol and clarified by centrifugation at 
10,000g for 10 min at 4 °C. Aliquots of supernatants were subjected to high 
performance liquid chromatography (HPLC) coupled with tandem mass 
spectrometry (LC-MS/MS) analysis. 





 The impact of free SMI#9 or SMI#9-AuNP on mitochondrial membrane 
potential (Δψm) on SUM1315 and HCC1937 TNBC cells was assessed using 
JC-1 (Mitocapture, Biovision, Mountainview, CA), a potentiometric green 
fluorescent dye that shifts to red fluorescence within mitochondria with a 
normal negative Δψm. Briefly, cells were incubated with the MitoCapture 
reagent for 15 min at 37 °C and imaged by fluorescence microscopy. The 
percent of cells showing > 5 punctate J-aggregates was scored by counting 
three-five fields of 50-100 cells in each field. To quantitate mitochondrial 
membrane potential changes, 20 × 103 SUM1315 or HCC1937 cells were 
seeded in 96-well plate and treated for 48 h with 5 μM SMI#9-AuNP or blank-
AuNP. Cells were then incubated with 10 μM JC-1 for 30-60 min, and the red 
and green fluorescence intensities of JC-1 were measured at 
excitation/emission = 490/525 nm and 490/590 nm with a Synergy 2 
fluorescence reader. Results were expressed as the ratio of red to green 
fluorescence. 
 4.2.7 LC/MS-MS analysis of SMI#9 
 SMI#9 concentrations in the plasma and tumors were determined by 





tissue homogenates were extracted with ethyl acetate. The organic phase 
was dried down and reconstituted in the mobile phase [methanol/0.45% 
formic acid in water (60:30, v/v)]. LC/MS-MS was performed on a Waters 
Xevo TQ-XS LC/MS-MS system with a Waters Xterra MS C18 column and 
isocratic elution with the mobile phase. SMI#9 was monitored at the positive 
electrospray ionization mode at m/z 366.69 > 150.1 mass transitions. 
 4.2.8 Inductively coupled plasma mass spectrometry analysis of gold 
 Organs and tumors were digested with aqua regia (hydrochloric acid: 
nitric acid, 3:1 v/v) and analyzed using an Agilent 7700× inductively coupled 
plasma mass spectrometry (ICP-MS) equipped with an Agilent ASX-500 series 
autosampler. External calibration using standards with internal standard 
correction of bismuth (Bi) was performed prior to the measurements. AuNP 
biodistribution data were expressed as a percentage of injected dose of 
gold/gram dry tissue. 
 4.2.9 Statistical analysis 
Each experiment was performed in triplicate and reproduced at least 
three times. Data are expressed as mean ± S.D, and P < 0.05 determined by 







4.3.1 AuNP conjugates characterization 
The chemical compositions of AuNP and SMI#9-AuNP were 
determined by TGA. Figure 4.1A shows the TGA curves of MSA-AuNP (blank-
AuNP) and MSA-AuNP conjugated SMI#9 (SMI#9-AuNP) with weight loss of 
6.15% and 13%, respectively, at 800 °C. The number of gold atoms was based 
on size determined by transmission electron microscopy (TEM) and gold 
density. The weight of 1 molar AuNP (W) with a diameter (D) of 4 nm can be 













The molecular weight of MSA (C4H6O4S) and SMI#9 (C17N6H14O4) are 
150 g/mol and 366 g/mol, respectively. The weight loss, 93.85%:6.15% = 





























The weight loss, 100%:6.6%:8.3% = AuNP: MSA:SMI#9, corresponds to 












This means that 26% of all possible reactive sites (170 MSA molecules 
carrying 340 –COOH groups) are conjugated with SMI#9. 
Figure 4.1B shows the UV-vis spectra of AuNPs before and after 
conjugation with modified SMI#9. The surface plasmon resonance (SPR) 
absorption peak of freshly prepared AuNPs is 508 nm, which corresponds to 
AuNP diameter range of 3-5 nm. However, upon conjugation with modified 
SMI#9, the SPR absorption peak broadened and shifted to 524 nm, which is 
indicative of particle aggregation. The size of SMI#9-AuNPs was also 
determined by TEM (Figure 4.1C) and AFM (Figure 4.1D) which showed a size 
of 32 nm and 40.2 ± 1.4 nm, respectively, that is consistent with aggregation. 
DLS further verified the average size of SMI#9-AuNP nanoconjugate at 41 nm 
as compared to 4.8 nm for AuNP. The zeta potential of MSA-capped AuNP 












Figure 4-1 SMI#9-AuNP characterization. A) thermogravimetric analysis. B) 
UV–vis spectroscopy. C) Transmission electron microscopy. D) Atomic force 





panel D(a) shows a white line from where the AFM sectional height profile in 
panel D(b) was taken and shows 39 nm particle width (two arrows). 
 
4.3.2 Intracellular SMI#9-AuNP uptake and releases 
To determine SMI#9-AuNP uptake and intracellular release of the 
conjugated SMI#9, MDA-MB-231 or SUM1315 cells were exposed to SMI#9-
AuNP, blank-AuNP, SMI#9 or untreated, and cell lysates analyzed by FTIR or 
LC-MS/MS. Control cell lysates spiked with (parent) SMI#9 were included as 
reference controls. FTIR analysis of SMI#9 (Figure 4.2A), and lysates 
prepared from SMI#9-AuNP treated MDA-MB-231 cells or MDA-MB-231 
control lysates spiked with SMI#9 showed characteristic nitro group banding 
at ~ 1550 cm-1 , indicative of SMI#9 presence (Figure 4.2B).  
 
Figure 4-2 FTIR spectra of A) chloroform/methanol (11:1, v/v) without (green) 
and with SMI#9 (red). And of B) SMI#9-AuNP treated and control MDA-MB-






SMI#9 was modified to enable conjugation to AuNP via an ester bond 
(Figure 4.3 A, a).  Intracellular hydrolysis would result in release of modified 
SMI#9 with the molecular weight of 396.3, which would theoretically 
produce parent ions at 397.3 ([M+H]+) and product ions at 150.1 (Figure 4.3 
A, b and c). Although no peak was detected under the transition of 397.3 > 
150.1 in SMI#9-AuNP treated cells, a strong peak was detected under 
m/z 381.3 > 150.1 transition in SMI#9-AuNP treated cells (at both 8 and 24 
h) but not in blank-AuNP or untreated control cultures (Figure 4.? C). Release 
of drug with 381.3 molecular mass could theoretically arise by 
dehydroxylation of hydroxymethylated SMI#9; however, the precise 
structure of intracellularly released drug and its metabolic processing is 
under investigation. The peak signals were stronger at 8 h as compared to 24 
h, suggesting rapid intracellular processing. The positive control cells treated 
with free (parent) SMI#9 showed the expected peak under m/z 366.69 > 
150.1 transition.  These results suggest efficient uptake and rapid 






Figure 4-3 LC-MS/MS analysis of SMI#9 release. A) (a) Chemical structures of 
parent SMI#9 (MW = 366.1), and AuNP-conjugated hydroxymethylated 
SMI#9 (MW = 396.3). (b) Predicted fragmentation pathway of SMI#9 under 
the MS condition. (c) Proposed mechanism of SMI#9 release from AuNP 
conjugate. B) and C) Chromatograms of SUM1315 extracts prepared at 8 or 
24 h from untreated (control), or cells treated with blank-AuNP (blank NP), 5 





m/z 366.69 → 150.1 for SMI#9 (B) or m/z 381.3 → 150.1 for SMI#9 released 
from AuNP (C). 
 
4.3.3 In vivo evaluation of SMI#9 and SMI#9-AuNP 
SMI#9 concentrations in plasma were measured by LC-MS/MS at 5 min 
to 24 h after a single intravenous injection of SMI#9 or PEGylated SMI#9-
AuNP. Following injection of the unconjugated drug, SMI#9 achieved 
maximum plasma concentration (Cmax) of ~74 nM at 5 min, and was rapidly 
cleared by 30 min (Figure 4.4A). In contrast, following injection of SMI#9-
AuNP, SMI#9 was slowly released and achieved Cmax of ~1200 nM at 8 h 
(Figure 4.4B). These data suggest that SMI#9 is not only released from the 
PEGylated SMI#9-AuNP conjugates but can also achieve higher systemic 
exposure as compared to the unconjugated SMI#9.   
Post-synthesis surface modification of SMI#9-AuNP with PEG was 
performed as PEG improves colloidal stability and prevents aggregation (143, 
144). Furthermore, PEG reduces adsorption of cellular proteins and increases 
the circulation time of nanoparticles. We first determined whether 
PEGylated SMI#9-AuNP similarly sensitizes TNBC cells as non-PEGylated 





SMI#9-AuNP or PEGylated SMI#9-AuNP (or blank-AuNP) and the responses 
measured by MTT assays. SUM1315 cells responded similarly to both 
formulations with GI50 values (based upon SMI#9 concentration) of ~0.75-1 
M, verifying that tethering of PEG did not significantly affect the activity of 
SMI#9 payload (Figure 4.4C). To compare the in vivo effects of SMI#9 and 
PEGylated SMI#9-AuNP or blank-AuNP on TNBC xenografts, MDA-MB-468 or 
SUM1315 TNBC cells were orthotopically implanted in female nude mice. 
When the tumors reached ~150 mm3, mice were randomized and treated 
twice weekly with vehicle, SMI#9, PEGylated SMI#9-AuNP or blank-AuNP. To 
overcome SMI#9 solubility limitations and to facilitate easy tumor access, 
unconjugated SMI#9 (or vehicle) was administered intratumorally whereas 
blank-AuNP and SMI#9-AuNP were injected intraperitoneally to assess 
tumor accessibility and bioavailability. Animal body weights were measured 
twice weekly to monitor animal health. SMI#9 or SMI#9-AuNP treatments 
significantly inhibited growth of MDA-MB-468 and SUM1315 xenografts as 
compared to the corresponding vehicle or blank-AuNP control groups (P ≤ 
0.05; Figure 4.4D and E). Compared to the control tumors that contained 





(Figure 4.4F) and SUM1315 (Figure 4.4G) tumors showed sparsely populated 
tumor tissues containing apoptotic cells (arrows in insets of Figure 4.4F and 
G). H&E staining showed lung tissues with normal architecture in both 
control and SMI#9 or SMI#9-AuNP treated groups (Figure 4.4H). The data in 
Figure 4.4I show that SMI#9 and SMI#9-AuNP treated mice maintain body 
weights comparable to vehicle or blank-AuNP controls suggesting drug 






Figure 4-4 SMI#9-AuNP inhibits TNBC growth. Pharmacokinetic analysis of 
unconjugated SMI#9 (A) and PEGylated SMI#9-AuNP (B) administered 
intravenously at 5 mg/kg body weight. C) In vitro activities of SMI#9-AuNP 
and PEGylated SMI#9-AuNP on SUM1315 cell proliferation. Results are mean 
± SD of triplicates from two independent experiments. Tumor volumes 
(mean ± SEM; n = 6 mice/group) of MDA-MB-468 (D) or SUM1315 (F) 
xenografts treated with unconjugated SMI#9 (1.5 mg/kg body weight), 
PEGylated SMI#9-AuNP (0.85 mg/kg body weight), or controls. P < 0.0001 by 
one-way ANOVA. Vertical scatter plots of excised tumor mass of MDA-MB-






4.3.4 Biodistribution of SMI#9-AuNP 
To verify whether the tumor growth inhibition in SMI#9-AuNP–treated 
mice resulted from SMI#9 release from the nanoconjugate, we quantitated 
SMI#9 levels in tumor fragments collected at sacrifice by LC/MS-MS. 
Compared with the control groups, measurable amounts of SMI#9 were 
detected in SUM1315 and MDA-MB-468 tumors treated with SMI#9 or 
SMI#9-AuNP (Figure 4.5 A and B). However, there was variability in the 
detected levels, which could have potentially resulted from tumor tissue 
samplings as tissue fragments rather than whole tumors were used for 
analysis or from loss of SMI#9 resulting from therapy-induced tumor cell 
death in the responsive tumors. 
Next, we determined the biodistribution and retention of AuNPs in 
tumor and organ tissues collected at sacrifice (Figure 4.5 C) by ICP-MS. The 
injected dosage of gold was calculated on the basis of the TGA data: weight 
ratio of gold to SMI#9 equivalent to 1:0.083 in the nanoconjugate (143). Thus, 
a SMI#9 dosage of 0.85 mg/kg body weight corresponds to gold dosage of 





per injection is 0.2 mg and the total gold injected is 1.8 mg after nine 
injections. Among the tissues analyzed, liver and tumors showed the highest 
accumulation of gold ranging from 0.19% to 0.4%; however, there were no 
significant differences in gold content between livers and tumors of blank 
AuNP and SMI#9-AuNP groups (Figure 4.5 C). Despite multiple injections, this 
accumulation was comparable with those reported for a single injection 
(145). AuNP bioaccumulation in liver and spleen are regulated by the 
reticuloendothelial system (RES; (146)). The low levels of AuNP accumulation 
in the spleen potentially reflect the low AuNP doses administered in our 
study and/or the time intervals between the injections. Furthermore, 
because the tissue samples were collected 3 days after the last AuNP 
injection, larger increases in gold depositions were perhaps not observed 
because of active renal clearance. The AuNPs used here are 5-nm particles 
with a hydrodynamic size of 41 nm following SMI#9 conjugation. Because the 
kidney filtration threshold is 6–8 nm (147), AuNPs that were stripped off their 
SMI#9 cargo would be small enough to be cleared by the kidneys leaving 
behind the non-biodegraded SMI#9-AuNPs. Because tumors contained 





(EPR) effects from leaky vasculature in the tumors contributed to 
accumulation of gold in the tumors (Figure 4.5 C). 
 
Figure 4-5 SMI#9 and gold biodistribution analysis. LC/MS-MS analysis of 
SMI#9 tumor levels and corresponding vertical scatter plots of SUM1315 (A) 
or MDA-MB-468 (B) excised tumor mass at sacrifice. C) ICP-MS analysis of 
accumulated gold in the indicated tissue. Data were analyzed by one-way 







Intratumoral injection of SMI#9, a clinically unsuitable mode of drug 
administration, was necessary because of its poor solubility and poor 
pharmacokinetic properties. Delivery of SMI#9 as a prodrug–AuNP conjugate 
not only greatly improved its circulation stability and drug exposure, but also 
allowed for a clinically acceptable mode, that is, systemic administration of 
the drug because of improved solubility. In this work we evaluated the 
toxicity, biodistribution, and therapeutic activity of systemically 
administered PEGylated SMI#9-conjugated AuNPs to assess their utility as a 
drug delivery platform for treatment of BRCA1 wild-type and BRCA1-mutant 
TNBCs.  
Perrault and colleagues (148) tested AuNPs with size range of 10–100 
nm and found that although AuNPs with hydrodynamic diameter of 60–100 
nm with PEGylation efficiently utilize EPR effect for enhanced tumor 
accumulation, these larger AuNPs penetrated weakly into the tumors and 
localized in the perivascular regions. AuNPs are generally considered 





are found to be toxic (149). AuNPs of larger size (35–50 nm) were found to 
enter cells more efficiently without toxicity than small nanoparticles (1.4 nm; 
(150)). Consistent with these data, our results show that 41-nm SMI#9-
AuNPs are taken up efficiently by tumor cells and display no apparent toxicity. 
Quantitative analysis of AuNP biodistribution by ICP-MS analysis showed 
higher accumulation of gold in tumors and liver as compared with other 
organs of SMI#9-AuNP and blank AuNP–treated mice. These data are in 
agreement with other studies that showed maximal accumulation of 
nanoparticles in the liver regardless of their size, shape, dosage, or 
composition (146, 151, 152). However, our data suggest that the AuNPs are 
actively cleared because the amounts of gold deposited in the liver and other 
tissues despite repeated injections resemble those in mice receiving a single 
dose. Because the AuNPs used in our study have a 5-nm core diameter and 
a hydrodynamic size of 41 nm for the SMI#9 nanoconjugate, our data suggest 
that the majority of AuNPs are stripped off their SMI#9 payload rendering 
them small enough for renal clearance (147). These data are consistent with 
those reported by Perrault and colleagues who showed rapid clearance of 





in the spleen and liver (148). Regardless of the coating layer, nanoparticles 
always form a “protein corona” when encountering physiologic conditions 
(153, 154). This corona phenomenon potentially balances out any 
differences between blank AuNP and SMI#9-conjugated AuNP during 
circulation and may explain the similar patterns of biodistribution data. It is 
noteworthy that despite high accumulation of gold in the tumors of blank 
AuNP–treated mice, tumor growth was unaffected in these mice providing 
further support for SMI#9 therapeutic activity and the nontoxicity of AuNPs. 
Although tumor growth was robustly inhibited by SMI#9-AuNP, the 
treatment did not affect body weights or induce overt toxicity as determined 
by necropsy and histopathologic analysis of the major vital organs. 
4.5 Conclusions 
In summary, the mechanistic data presented here show that AuNP is 
a suitable vehicle for delivering SMI#9 and that the chemically modified 
SMI#9 released from AuNP functions similarly as the free parent SMI#9.  we 
demonstrated the therapeutic utility of an AuNP-based platform for 
delivering Rad6 inhibitor for treating BRCA1 wild-type and BRCA1-mutant 





therapies. SMI#9 delivery as a prodrug–AuNP conjugate not only improved 
its pharmacokinetic properties but also allowed for a clinically acceptable 
(systemic) mode of drug administration that inhibited TNBC growth. There 
was no evidence of blank or SMI#9-AuNP–induced toxicity as measured by 
their impact on animal body weight and organ histopathology.  
 
CHAPTER 5 SIZE-DEPENDENT TOXICITY OF GOLD NANOPARTICLES 
 This chapter is reproduced with permission from the Small, 12, no. 5 
(2016): 631-646. Marie‐Claude Senut, Yanhua Zhang, Fangchao Liu, Arko 
Sen, Douglas M. Ruden, Guangzhao Mao, “Size-dependent toxicity of gold 
nanoparticles on human embryonic stem cells and their neural derivatives”. 
5.1 Introduction 
Nanotoxicology is an emerging discipline studying the interference of 
engineered nanomaterials with the functions of cellular and extracellular 
nanomachineries.(155) The accelated pace of clinical trials and 
commericalization of nanomaterials places increased demands on 
toxicological evaluations of engineered nanomaterials.(156) There is an 





assessment methods for nanomaterials due to their unique size range, 
surface chemistry, and interactions with biological systems.(157) 
Nanomaterials have the potential to cross the placental and the blood-brain 
barriers(2, 158) or, in a few examples, be transported to the central nuervous 
system (CNS) without crossing the blood-brain barrier.(159-162) 
Neurotoxicity of engineering nanomaterials will become more relevant with 
the development of CNS-targeting nanomedicine.  
Because of the wide biomedical applications of AuNPs, human 
exposure to AuNPs will be increasingly likely, which warrants careful 
evaluation of their toxicological effects. AuNPs have been described by most 
studies as nontoxic,(139, 163-165) but some studies have found them to be 
toxic.(166-172) AuNPs with 1.4-1.5 nm in diameter have been found to be 
highly toxic to cells.(168, 173) A few in vitro and in vivo studies have shown 
that chronic exposure to AuNPs might interfere with brain function. For 
example, a decrease in glutamate decarboxylase 1, an enzyme that is 
involved in GABA synthesis and is associated with several neurological 
disorders,(174) was observed in human HeLa cells exposed to gold 





to increase the proliferation in human neurosphere-derived neural 
precursor/pregenitor cells (NPCs)(176) and induce oxidative stress in a 
mouse immortalized NPC line.(177) In rodent models, intraperitoneal 
injections of 17-20 nm AuNPs resulted in learning and memory deficits 
associated with elevated dopamine levels and decreased serotonin 
levels,(178) as well as increased brain expression levels of markers of 
oxidative stress, apoptosis, and inflammation.(179) More recently, cultured 
mouse hippocampal CA1 neurons were shown to be more excitable when 
exposed to 5-40 nm AuNPs.(180) Taken together, these data demonstrate 
that AuNPs as tools for neuromedicine should be carefully evaluated since 
they may adversely alter neuronal differentiation, synapse formation, and 
functional plasticity (which affect memory and learning) in a size-dependent 
manner.  
Currently, there are no systematic methods to predict toxicological 
effects of AuNPs on human health. A majority of neurotoxicological 
assessments are conducted in vitro using immortalized cell lines with 
standard toxicological assays such as the MTT (measurement of 





disruption) assays with short exposure time (usually limited to within 48 
hours). One shortcoming of standard in vitro toxicity assays, however, is that 
the potential interference of nanoparticles with embryonic development 
cannot be clearly addressed. Furthermore, it is often difficult to correlate 
outcomes from animals to humans. Human embryonic stem cells 
(hESCs)(181) and their subsequent differentiation into NPCs and neurons 
have enabled researchers to establish pluripotent cell-based models to study 
developmental neurotoxicology. This process mimics aspects of the early 
stages of human brain development, giving us a unique opportunity to 
identify the effects of exposure to nanomaterials on neural specification. 
Some significant advantages in using hESCs compared to other (e.g., animal-
derived) systems are that 1) they have unlimited self-renewal capabilities 
and can be grown indefinitely in the laboratory; 2) they can differentiate into 
a variety of specialized cell types, such as neurons; 3) they preclude species-
specific differences, making them a better model to predict human response 
to toxins; and 4) subtle changes in cell functionality rather than cell death 
can be tested on nanomaterials of low toxicity such as AuNPs. Recently, 





This chapter describes the morphological and epigenetic effects of 
AuNPs of three core sizes (1.5 nm, 4.0 nm, and 14 nm) on the neuronal 
differentiation of hESCs. The 1.5 nm AuNP (AuNP1.5) was chosen because 
AuNPs of this size have been found to be highly toxic to cells.(168, 173) 
AuNP4 and AuNP14 are within the size range widely used for targeted drug 
delivery applications including those targeting the brain.(2, 3) The 
nanoparticle size and surface chemistry were characterized by UV-vis, AFM, 
TEM, and zetasizer. We show that AuNPs have size-dependent differential 
effects on the viability, pluripotency, and neuronal differentiation potentials 
of hESCs.  
5.2 Experimental methods 
5.2.1 Materials 
Gold(III) chloride trihydrate (HAuCl4·3H2O, 99% metal trace), 
chloro(triphenylphosphine)gold(I) (AuCl(PPh3), 97%), sodium citrate tribasic 
dehydrate (≥99%), MSA (97%), borane tert‐butylamine complex (97%), 
sodium borohydride (NaBH4) (98%), polyamidoamine (PAMAM, 





solution), and bovine serum albumin (BSA, 98%) were all purchased from 
Sigma‐Aldrich. Sodium hydroxide (98%) was purchased from Fisher Scientific. 
5.2.2 AuNP Synthesis and Characterization 
Thiolate‐capped 1.5 nm ultrasmall AuNP (AuNP1.5) were synthesized 
by modifying a literature procedure.(184) The Au(I) precursor AuCl(PPh3) 
(0.375 mmol) was partially dissolved in 21 mL ethanol at room temperature 
under vigorous stirring (600–800 rpm). Tert‐butylamine‐borane (3.75 mmol) 
was used as a mild reducing agent, and 2 h after its addition, MSA (0.15 mmol) 
was added to control the particles size.(185) Mercapto‐alkyl acids have been 
found to be effective in stabilizing ultrasmall AuNPs in aqueous solution. The 
final AuNP ethanol solution was washed and purified by ultracentrifugation 
using MW10000 Amicon centrifuge tubes in deionized water repeatedly. 
MSA-capped 4 nm AuNP (AuNP4) were synthesized following a modified 
literature procedure.(16) A 500 mL aqueous solution containing 0.25 × 10−3 
M of HAuCl4·3H2O and 0.25 × 10−3 M of trisodium citrate was prepared in an 
Erlenmeyer flask under vigorous stirring at room temperature. Then, 15 mL 
of ice cold 0.1 M NaBH4 solution were added to the solution, resulting in a 





adjusting the pH of the solution to 11 with 0.1 M NaOH solution, 50 mg MSA 
was added and the solution was stirred for 12 h. The final solution was 
concentrated to 2.5 g (gold) L−1 by ultracentrifugation using MW10000 
Millipore Amicon centrifuging units and washed by deionized water several 
times. 
Citrate-capped 14 nm AuNP (AuNP14) were synthesized using the 
Turkevich method.(186, 187) In a typical synthesis, a 500 mL aqueous 
solution containing 0.25 × 10−3 M HAuCl4·3H2O was heated to boil and then 
175 mg of sodium citrate dissolved 30 mL water solution was directly poured 
into the reaction mixture. The color of the reaction turned gray, pink, and 
finally wine-red. The final solution was concentrated to 2.5 g (gold) L−1 by 
ultracentrifugation using MW10000 Millipore Amicon centrifuging units and 
washed by deionized water several times.  
To apply the BSA coating, nanoparticle with concentration of 1 mg 
(gold) ml-1 of deionized water was incubated overnight with 400 mg BSA. 
Varian Cary 50 UV–vis absorption spectroscopy was used to determine 






TEM images of AuNPs were taken on JEOL JEM‐2010. The samples 
were prepared by placing a droplet of the AuNP solution on a Formvar‐
coated copper TEM grid. Excess liquid was removed by a piece of filter paper 
under the grid and dried in the air. The working voltage was 200 keV and the 
current was 109 mA. At least 50 particles were measured on the same 
sample to yield an average particle size. 
DLS and zeta potential were measured using a Malvern Nano‐ZS. 1 mL 
solution was transferred to a 2.0 mL polystyrene cuvette. The Z‐average 
hydrodynamic diameter (HD), polydispersity index (PDI), and zeta potential 
were measured at 25 °C. 15 scans were performed in each measurement. 
5.2.3 Cell culturing and assay study 
Human Embryonic Stem Cell Cultures: The NIH‐approved and 
registered WA09 hESC line (passages 26–32; WiCell Research Institute, 
Madison, WI, USA)(188) was maintained in a humidified incubator at 37 °C 
with 5% CO2 as previously described.(189) Briefly, cells were grown on a 
feeder layer of irradiated mouse embryonic fibroblasts (GlobalStem, 
Rockville, MD, USA) in hESC culture medium made of 20% knockout serum 





penicillin/streptomycin (all products from Life Technologies Corporation, 
Carlsbad, CA), 4 ng mL−1 human fibroblast growth factor basic (FGF2, 
Peprotech, Rocky Hill, NJ), and 0.1 × 10−6 M 2‐mercaptoethanol (Sigma‐
Aldrich, St Louis, MO) in DMEM/F12 (Life Technologies Corporation, Carlsbad, 
CA). The active ingredient within the serum replacement is lipid‐rich albumin. 
hESCs were regularly passaged by mechanical dissection and their 
pluripotent state assessed by immunofluorescence detection for 
pluripotency markers, such as Oct4, Nanog, and Lin28. 
Trypan Blue Exclusion Assay: At the end of exposure, control and 
AuNP‐treated hESCs were harvested and stained with 0.4% Trypan blue (Life 
Technologies Corporation, Carlsbad, CA). Viable (unstained) and nonviable 
(dark‐blue stained) cells were counted with a hemocytometer. The number 
of viable cells was determined by subtracting the number of nonviable cells 
from the total number of cells counted and expressed as a percentage 
relative to the total number of cells. Data were collected from three 
independent experiments. 
MTT Assay: hESCs were cultured in phenol red‐free culture medium 





of AuNP exposure, the medium was supplemented with 0.5 mg mL−1 of MTT 
(Sigma‐Aldrich, St Louis, MO) freshly prepared in PBS, and cells were 
incubated in the dark at 37 °C for 3 h. MTT‐formazan crystals were then 
solubilized for 15 min, at room temperature in dimethyl sulfoxide (DMSO). 
Absorbance was measured at 590 nm using a spectrophotometer, and cell 
survival was expressed as a percentage of absorbance relative to that of 
control samples. Data were obtained from three separate experiments. 
Uptakes Studies by TEM: The cellular uptake of AuNPs was assessed 
on MEFs and undifferentiated WA09 cells (passage 32) exposed to vehicle or 
10 μg mL−1 AuNP14 for 48 h. At the end of exposure, cells were washed and 
fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in 
PBS. Samples were processed at the MSU Center for Advanced microscopy 
where they were postfixed in 1% osmium tetroxide, rinsed in distilled water, 
dehydrated through a graded series of acetone, and embedded in epoxy 
resin. Ultrathin 70 nm sections were obtained and then analyzed and 
photographed using a JEOL 100CXII electron microscope. 
Pluripotency In Vitro Studies: The effects of exposure to AuNPs on the 





spontaneous differentiation of EBs.(190) Briefly, EBs were generated by 
mechanical dissociation of hESC colonies and cultured for two weeks in FGF2‐
free hESC medium in presence of vehicle, 0.6 μg mL−1 AuNP1.5, or 10 μg mL−1 
of AuNP4 and AuNP14. At the end of exposure, total RNA was extracted from 
EBs using Qiazol (Qiagen, Valencia, CA) according to the manufacturer's 
protocol, quantified by optical density, and subjected to reverse 
transcription using Superscript II Reverse Transcriptase and random primers 
(Life Technologies Corporation, Carlsbad, CA) for 50 min at 40 °C followed by 
15 min at 75 °C. Quantitative PCR analyses of the well‐established lineage 
marker genes—endodermal (AFP and NODAL), ectodermal (NCAM and 
NESTIN), and mesodermal (BRACHYURY, PITX2, and LEFTY)—were 
performed using an ABI PRISM 7000 Sequence Detection System and its 
software (Applied Biosystems) with 10 ng cDNA, 400 × 10−9 M of each primers, 
and SYBR Green PCR Master Mix (Life Technologies Corporation, Carlsbad, 
CA). Resulting data were normalized against the expression of the internal 
control GAPDH gene. Data analysis was performed using the 2 − ΔΔCt 





mean centering, and autoscaling as previously described.(191) Data were 
collected from three separate experiments. 
Differentiation of hESCs into NPCs: Generation of NPCs from hESCs 
was performed as previously described.(189, 192) Following mechanical 
dissociation of hESC colonies, EBs were cultured in suspension for 4 d in 1:1 
hESC/N2 medium (Life Technologies Corporation, Carlsbad, CA), followed by 
4 d in N2 medium supplemented with 3 × 10−6 M retinoic acid (RA; Sigma‐
Aldrich, St Louis, MO), and 3 d in N2 medium added with 20 ng mL−1 FGF2 
(Peprotech, Rocky Hill, NJ). At this time, EBs were transferred to fibronectin‐
coated plates (20 μg mL−1 fibronectin; Life Technologies Corporation, 
Carlsbad, CA) and cultured in N2/FGF2 medium for an additional 8 d to obtain 
neural rosettes. The latter were subsequently dissociated and plated in 
N2/FGF2 medium on 10 μg mL−1 polyornithine/5 μg mL−1 laminin‐coated 
dishes. Cells were fixed in 4% paraformaldehyde and immunostained for the 
NPC marker Nestin (mouse anti‐Nestin; 1:500; EMD Millipore Corporation, 






Exposure of hESC‐Derived NPCs to AuNPs: hESCs‐derived NPCs were 
cultured on fibronectin‐coated six‐well dishes in N2/FGF2 medium and 
chronically exposed to vehicle or the different sized AuNPs for 72 h, at which 
time cells were fixed and immunostained for Nestin and the DNA marker 
DAPI. The total number of Nestin‐positive cells and DAPI‐stained nuclei were 
counted in five fields per well in three separate experiments, by an observer 
blind to the experimental conditions. The number of cells harboring pyknotic 
nuclei was also calculated. Total numbers were expressed as a percentage of 
the total number of cells, as evaluated by DAPI or Hoescht staining. 
Neuronal Differentiation of hESC‐Derived NPCs: Neuronal 
differentiation of NPCs derived from control and AuNP‐exposed hESCs was 
achieved as previously described.(189, 193) NPCs were cultured on 
polyornithine/laminin‐coated 12‐well dishes at a 5105 cells cm−2 density in 
N2 medium supplemented with 10 ng mL−1 brain‐derived neurotrophic factor 
(BDNF), 10 ng mL−1 glial cell‐derived neurotrophic factor (GDNF), 10 ng 
mL−1insulin‐like growth factor (IGF) (all factors from Peprotech, Rocky Hill, 
NJ), 200 ng mL−1ascorbic acid (Sigma‐Aldrich, St Louis, MO), and 100 ng 





neuronal marker microtubule‐associated protein 2 (MAP2) (mouse antibody; 
1:500, EMD Millipore Corporation, Billerica, MA). 
Morphological Analysis of MAP2‐Positive Cells: Determination of 
neuritic complexity of MAP2‐positive cells derived from control and AuNP‐
exposed hESCs was performed using Sholl analysis, as previously 
described.(189) Neurons were randomly selected for which neurites could 
be clearly identified and distinguished from neighboring cells. For each 
experimental condition, analysis of 18–27 neurons were performed blindly 
to well treatment. For each neuron examined, the average sum of crossings, 
the average maximal neuritic distance, and the average total number of 
branchings were recorded. 
Antibodies and Immunofluorescence Procedures: Immuno-
fluorescence staining was performed as previously described.(194) Following 
fixation in 4% paraformaldehyde, cells were rinsed in PBS, blocked in 3% 
donkey serum (Sigma‐Aldrich, St Louis, MO) in 0.3% Triton‐X‐100 (NDST3%), 
and incubated overnight at 4 °C with the primary antibodies diluted in 
NDST1%. After several rinses in NDST1%, cells were incubated for 2 h in the 





Life Technologies Corporation, Carlsbad, CA). Following rinses, cells were 
stained with the nuclear marker DAPI (Sigma‐Aldrich, St Louis, MO). 
Specificity of the immunostainings was assessed by replacing the primary 
antibodies with normal serum, and by omitting one immunoreagent of the 
immunostaining protocol. 
Statistical Analysis: Statistical significance between experimental 
groups was determined by Student's t‐test or one‐way analysis of variance 
(ANOVA) followed by a post hoc Holm–Sidak test when F value was 
significant, or Kruskal–Wallis one‐way ANOVA on ranks followed by Dunn's 
test using the SigmaPlot 12 software (SYSTAT Software Inc., San Jose, CA). 
Statistical significance was defined at p ≤ 0.05. Data are expressed as the 
mean ± SEM. 
Immunoprecipitation Based Colometric Assays: Global DNA 
methylation status of exposed and control hESCs were determined using 
MethylFlash Methylated DNA Quantification Kit (Catalogue No. P‐1034) and 
MethylFlash Hydroxymethylated DNA Quantification Kit (Catalogue No. P‐
1036) from Epigentek. Briefly, 200 ng of DNA was bound to the bottom of 





with capture antibody and detection antibody. The final colorimetric signal 
was normalized to the standard input DNA to estimate the overall 
methylation percentage. 
5.3 Results 
5.3.1 AuNP characterization 
All nanoparticles were synthesized following the methods described 
previously. The sizes of as synthesized AuNPs were confirmed with TEM and 
DLS (Figure 5.1). The diameters of AuNP core were determined to be 1.5 ± 
0.1 nm for AuNP1.5, 4.2 ± 0.5 nm for AuNP4, and 13.6 ± 0.4 nm for AuNP14, 
respectively (Figure 5.1 A). In order to prevent aggregation of AuNPs after 
addition of culture medium, AuNPs were incubated with bovine serum 
albumin (BSA) prior to the addition as BSA has been proved to be effective in 
restraining nanoparticle aggregation.(33, 195) An increase in particle 
hydrodynamic size of 4-6 nm was observed for AuNP4 and AuNP14 (Figure 
5.1 C), which indicates the formation of protein corona. The core size of both 
AuNP4 and AuNP14 remained unchanged according to UV-Vis spectrum, 
which shows no shift of absorption peak after incubating with BSA. (Results 






Figure 5-1 A) TEM images of AuNPs of average core diameters 1.5, 4, and 14 
nm; B) DLS measurements of AuNP1.5, AuNP4, and AuNP14 in deionized 








5.3.2 AuNP size effect on hESC viability 
To identify the potential AuNP toxicity, hESC were exposed to 10 μg 
mL-1 AuNPs, largely above the nontoxic range(37) for 24 hours. No 
remarkable differences in the growth and morphology of hESC colonies were 
observed with exposure of AuNP4 and AuNP14 at the end of the experiment 
compared to control cultures. In contrast, cells treated with AuNP1.5 
exhibited loss of cohesiveness, rounding up, and detachment, suggesting 
ongoing cell death, shown as Figure 5.2 A. Similar time-course and severity 
of AuNP1.5-induced cell loss were observed when hESCs were cultured on 
gelatin-coated plates instead of MEFs, suggesting a direct toxic effect of 
AuNP1.5 on hESCs (data not shown). Trypan blue assays, which stain dead 
cells, at the end of the 24 h treatment revealed statistically significant 
differences in the viability of hESCs between the different experimental 
groups (p< 0.001) (Figure 5.2 B). Thus, whereas no change in viability was 
observed among control, AuNP4- (p= 0.79), and AuNP14- (p= 0.89) treated 
cultures, a statistically significant 88% decrease in the number of viable 
hESCs was observed following treatment with AuNP1.5 (p< 0.001). 





mitochondrial function, provided comparable results with a statistically 
significant 85% decrease (p= 0.028) in cell viability in AuNP1.5-treated hESCs 
compared to controls (Figure 5.2 C). 
 
Figure 5-2 Exposure of hESC to AuNPs. A) WA09 hESC cell colonies on MEF 
feeder layer following 24 h exposure to vehicle, or 10 μg mL−1 of AuNP1.5, 
AuNP4, and AuNP14. Only colonies exposed to AuNP1.5 exhibited altered 
morphology suggestive of cell death. Arrows indicate MEFs with visible 
intracellular uptake of AuNPs in the case of AuNP4 and AuNP14. AuNP1.5 
was too small to be seen. The scale bar is 160 μm in the bright field 
microscopic images; B) Cell viability analysis of hESCs exposed for 24 h to 10 
μg mL−1 of the different sized AuNPs using Trypan blue assay; C) 
Measurement of mitochondrial activity in hESCs exposed for 24 h to 10 μg 
mL−1 of the different sized AuNPs by the MTT assay. 
 
In order to determine the dosage dependent toxicity of AuNP1.5, 





ranging from 0.001 to 10 μg mL−1. The Trypan blue exclusion assay revealed 
an IC50 value (the concentration necessary to kill 50% of the cells) of 1.45 μg 
mL−1 in this 4 d exposure experiment.  
5.3.3 AuNP cell uptake by hESC 
Cells are known to uptake nanoparticles mainly through endocytosis, 
and this process is dependent upon the size, shape, and surface chemistry of 
nanoparticles.(150, 163) As shown in Figure 5.2 A, intracellular accumulation 
of AuNP4 and AuNP14 could clearly be detected by optical microscopy in  
cultures of hESCs grown on MEFs after a 24  h exposure to 10 μg mL−1 
concentration. Using DAPI staining to visualize the differences in nuclear 
chromatin patterns that exist between MEFs and hESCs,(196, 197) we 
observed that the nuclei of AuNP-positive cells displayed the bright 
fluorescent heterochromatin foci, characteristic of proliferating and 
senescent MEFs(197) (Figure 5.3 A).  In MEFs, AuNPs appeared as black dots 
that distributed throughout the cellular cytoplasm, preferentially 
aggregating around the nucleus (Figure 5.3 B, 5.3 C). Because no clear uptake 
of AuNP1.5 could be observed in the cultures, we used the GoldEnhanceTM 





MEFs (Figure 5.3 D). In contrast, no accumulation of the AuNP1.5 observed 
in hESCs, even after the GoldEnhanceTM treatment (data not shown). Based 
on this result, we observed no visible intracellular entry of AuNP1.5 at 
sublethal dosages. 
 
Figure 5-3 Uptake of AuNPs by MEFs but not hESCs. A) Cell cultures stained 
with the nuclear marker DAPI showing the bright heterochromatin foci 
characteristic of MEFs (long arrows), which allow to distinguish them from 
hESCs(arrowheads). Uptake of B) AuNP4 and C) AuNP14 was clearly visible in 
MEFs, but not in hESC colonies (region marked by *) delineated by dotted 
lines. D) Uptake of AuNP1.5 by MEFs was only visible following intensification 








5.3.4 AuNP effect on hESC pluripotency and differentiation 
The pluripotency of hESCs enables them to differentiate into multiple 
tissue types. Here we determined the effects of AuNP exposure towards the 
capabilities of hESCs to generate ectodermal, mesodermal, and endodermal 
derivatives. To this end, we passively differentiated hESC-derived embryoid 
bodies (EBs) for 2 weeks in basic fibroblast growth factor (bFGF)-free stem 
cell medium, while exposing them to either AuNPs or vehicle. The 
concentration for AuNP4 and AuNP14 was 10 µg mL-1 while a sublethal 
dosage of 0.6 µg mL-1 was used for AuNP1.5. As shown in Figure 5.4, 
quantification of marker mRNAs indicated that there were no statistically 
significant differences in the expression levels of NCAM (Figure 5.4 A), 
NESTIN (Figure 5.4 B), BRACHYURY (Figure 5.4 C), PITX2 (Figure 5.4 D), LEFTY 
(Figure 5.4 E), NODAL (Figure 5.4 F) and AFP (Figure 5.4 G). These gene 
expression results suggest that, at the concentrations tested, exposure to 






Figure 5- 4 Characterization of the effects that 14 d exposure to AuNP1.5 (0.6 
μg mL−1), AuNP4 (10 μg mL−1), and AuNP14 (10 μg mL−1) has on the 
capability of hESCs to passively differentiate into cells of the three germ 
layers. 
 
To examine the effects of exposure to various sized AuNP on the 





throughout the entire neural differentiation protocol (19 days) in presence 
of vehicle or 10 μg mL-1 AuNP1.5, AuNP4, and AuNP14. The presence of 
AuNP4 and AuNP14 in the medium did not prevent the formation of EBs, 
which appeared morphologically similar to those generated from vehicle-
exposed EBs (Figure 5.5). In contrast, AuNP1.5-exposed hESCs did not form 
EBs but rather rapidly disintegrated into single cells within 48 hours of 
treatment, so that by day 3, no EBs survived (Figure 5.5). Therefore, 
following experiments were carried out using a 0.6 μg mL-1 (EC30) 
concentration for AuNP1.5, which allowed the formation of EBs. During 
neural differentiation, both control and AuNP1.5-treated EBs were able to 
generate neural rosettes (Figure 5.5). However, the neural rosettes formed 
by AuNP1.5-exposed EBs were small, exhibiting a dark aspect (Figure 5.5), 
and did not survive. The data suggest that even at sublethal dosage AuNP1.5 











Our data show that thiolate-capped AuNP4 and citrate-capped 
AuNP14 are nontoxic to hESCs and do not affect hESC pluripotency or 
neuronal differentiation into NPCs. Our data also show that thiolate-capped 
AuNP1.5 is toxic to hESCs with an IC50 value measured during 4-day exposure 
of 1.45 μg mL−1 (or 0.0706 M). At first glance, our results appear to be 
consistent with other reports, in particular, the one on size-dependent 
cytotoxicity of AuNPs.(198) The paper showed that AuNPs of 15 nm in size 





lines (SK-Mel-28 human melanoma, HeLa human cervix carcinoma, L929 
mouse fibroblasts, and J774A1 mouse macrophages). However, a closer 
examination points to major differences between the current study and the 
previous studies. In a previous report, Au55 cluster with a diameter of 1.4 nm 
capped by triphenylphosphine monosulfonate (TPPMS), denoted as 
Au1.4MS, was found highly toxic to a number of human cancer and healthy 
cell lines.(168) The IC50 value of Au55 was determined to be 0.62 M for 
fibroblast cells measured at 24 h.(168) Au1.4MS was found to cause necrosis 
by oxidative stress and mitochondrial damage.(173) A subsequent study 
showed that when the phosphine ligand was replaced with a thiol ligand, 
glutathione (GSH), Au55 cytotoxicity was greatly reduced.(173) The authors 
attributed the toxicity of Au1.4MS to weak phosphine/metal binding that 
allows surface gold atoms to interact directly with biological targets. 
However, in our study, we found that even thiolate-capped Au55 is toxic to 
MEFs and hESCs. In addition, the IC50 of hESCs is much less than the values of 
fibroblast and cancer cells, which indicates that hESCs are more sensitive to 
nanoparticle perturbations. The other major finding of this study is that 





differentiation without obvious intracellular uptake. This observation argues 
for the AuNP1.5 interactions with the cell membrane as the cause of its 
cytotoxicity.  
In the literature, several mechanisms of AuNP cytotoxicity have been 
proposed. One is the size match between Au55 and the DNA major groove 
and Au55 irreversible coordination to DNA.(168) The second is the induction 
of reactive oxygen species (ROS) formation due to Au55’s electronic/catalytic 
properties (it excites O2 but is not oxidized itself). Transition metals such as 
gold are capable of one-electron reduction of oxygen and production of 
reactive oxygen species such as superoxide radicals, hydrogen peroxide, and 
hydroxyl radicals, which then can cause oxidation of biomolecules.(199, 200) 
The third mechanism is Au55’s capability to block membrane ion channel.(201) 
In another study of AuNP surface functionalities on zebrafish embryonic 
gene expression, 2-mercaptoethanesulfonic acid (MES)-capped 1.5 nm 
AuNPs were found to affect ion channel transport mechanism signaled by 
misregulated gene expression.(202) It has been suggested that such gold 





controlled.(155, 203) Our data are more consistent with the third mechanism 
of AuNP1.5 interfering with membrane ion channel functions. 
5.5 Conclusions 
This work described effect of AuNPs with core size of 1.5, 4, and 14 nm 
on hESC viability, cell uptake, pluripotency, and differentiations. AuNPs were 
used as model nanoparticles due to their versatile surface chemistry, ease of 
imaging, and tunability for targeted drug/imaging agent delivery. We found 
that hESC colonies exposed to 1.5 nm MSA-capped AuNPs exhibited loss of 
cohesiveness, rounding up, and detachment suggesting ongoing cell death. 
The hESCs exposed to 1.5 nm AuNPs did not form EBs but rather rapidly 
disintegrated into single cells within 48 h of treatment. Cell death caused by 
1.5 nm AuNPs also occurred in the treatment with hESC-derived neural 
precursor/progenitor cells. None of the other nanoparticles exhibited 
toxicity to the hSECs or their derivatives in experiments lasting as long as 19d. 
In contrast to some reports, we found that Au55 capped by the strongly 
binding thiolate could still be toxic to cells. Our data suggest that hESC uptake 





significant amount of AuNPs inside the hESCs while AuNPs were clearly 
present inside the MEF feeder cells.  
CHAPTER 6 CONCLUSIONS 
 This dissertation described a novel way to achieve targeted delivery of 
a type of neural therapeutic drug, which could bypass blood-brain barrier, 
without introducing noticeable side effect. The method is obtained by 
engineering the surface of gold nanoparticles followed by conjugation with 
drug and targeting protein. The stability of the nanoconjugates has been 
characterized, potency was tested on established animal model and recovery 
was detected. The releasing kinetics was also undergoing further research. 
 This dissertation also described a nontoxic way to increase solubility 
and bio-accessibility of anti-cancer drug by conjugating the drug with 
surface-modified gold nanoparticle. The decrease of tumor size was 
observed after administration of the nanoconjugate, and the biodistribution 
study was conducted. 
 In conclusion, a careful engineering of the gold nanoparticle gives a 
good opportunity to improve performance of neural therapeutic drugs and 





that gold nanoparticle with size larger than 2 nm in diameter is nontoxic, 
which is also discussed in this dissertation. The engineering of gold 
nanoparticle to achieve biocompatible nanoconjugates has a great potential 
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Due to their ease of synthesis, versatile surface chemistry, ease of 
imaging, and biocompatibility, gold nanoparticles (AuNPs) are employed as 
drug delivery devices in the treatment of respiratory problems associated 
with spinal cord injury (SCI). We have developed a method for the synthesis 
of a tripartite nanoconjugate comprised of an AuNP drug carrier chemically 
conjugated to a transporter protein (wheat germ agglutinin coupled to 
horseradish peroxidase or WGA-HRP) and to potent SCI drugs. The 
therapeutic efficacy and biodistribution were studied in a validated animal 
model. Our results show that a single administration of the nanoconjugate 





systemic drug dosage and restored the respiratory drive. The effects lasted 
for 4 weeks. A biodistribution study using inductively coupled plasma mass 
spectrometry on the same animal model shows that the nanoconjugate was 
successful in targeting the respiratory neurons in the medulla by detecting 
the presence of gold in the medulla and spinal cord. The AuNPs are also 
applied in triple negative breast cancer treatment. By conjugating the 
surface modified AuNPs with a non-soluble drug, the solubility has been 
increased and introduced cancer cell death after administration. The 
nanoconjugate structure was determined by UV-vis spectroscopy, 
transmission electron microscopy, dynamic light scattering, 
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